

BC1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
13 February 2003 (13.02.2003)

PCT

(10) International Publication Number  
**WO 03/012070 A3**

(51) International Patent Classification?: **C12P 21/06**,  
C12N 1/20, 15/00, 15/63, C07H 21/04, C07K 1/00, 16/00

45040-9462 (US). **AXELROD, Douglas, W.** [US/US];  
The Procter & Gamble Company, Health Care Research  
Center, Box 1057, 8700 Mason Montgomery Road, Ma-  
son, OH 45040-9462 (US).

(21) International Application Number: PCT/US02/24764

(22) International Filing Date: 5 August 2002 (05.08.2002)

(74) Agents: **SMYTH, Robert, J.** et al.; Morgan, Lewis &  
Bockius LLP, 1111 Pennsylvania Avenue, NW, Washing-  
ton, DC 20004 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/309,495 3 August 2001 (03.08.2001) US  
60/317,975 10 September 2001 (10.09.2001) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZM, ZW.

(71) Applicants (*for all designated States except US*): **GENE  
LOGIC, INC.** [US/US]; 708 Quince Orchard Road,  
Gaithersburg, MD 20878 (US). **THE PROCTER &  
GAMBLE COMPANY** [US/US]; Health Care Research  
Center, Box 1057, 8700 Mason Montgomery Road, Ma-  
son, OH 45040-9462 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **JAISWAL, Neelam**  
[US/US]; The Procter & Gamble Company, Health Care  
Research Center, Box 1057, 8700 Mason Montgomery  
Road, Mason, OH 45040-9462 (US). **HOUGHTON,  
Adam** [US/US]; The Procter & Gamble Company, Health  
Care Research Center, Box 1057, 8700 Mason Montgo-  
mery Road, Mason, OH 45040-9462 (US). **MERTZ,  
Lawrence** [US/US]; 708 Quince Orchard Road, Gaithers-  
burg, MD 20878 (US). **Jl, Darren** [US/US]; The Procter  
& Gamble Company, Health Care Research Center,  
Box 1057, 8700 Mason Montgomery Road, Mason, OH  
45040-9462 (US). **COOK, Jonathan, S.** [US/US]; The  
Procter & Gamble Company, Health Care Research Center,  
Box 1057, 8700 Mason Montgomery Road, Mason, OH

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(88) Date of publication of the international search report:  
12 June 2003

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: GENE ASSOCIATED WITH BONE DISORDERS

(57) Abstract: The present invention relates to identifying genes that are differentially regulated or expressed in bone deposition disorders. Specifically, a novel gene has been identified as being differentially regulated during the maturation of osteoblasts and whose expression can be correlated, for example, with bone deposition disorders such as osteoporosis (including correlation with degrees of severity of the disease).



WO 03/012070 A3

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/24764

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12P 21/06; C12N 1/20, 15/00, 15/63; C07H 21/04; C07K 1/00, 16/00  
US CL : 435/69.1, 69.2, 252.3, 320.1, 455; 536/23.1; 530/350, 387.1; 800/21

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 69.2, 252.3, 320.1, 455; 536/23.1; 530/350, 387.1; 800/21

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
STN AND WEST; Commercial sequence data bases for SEQ ID NOS : 1 & 2.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Database on Genbank, NAGASE et al. Prediction of the coding sequences of unidentified human genes. XV. The complete sequences of 100 new cDNA clones from brain which codes for large proteins in vitro. 11 November 1999, Accession No. AB033025. [Accession No. AB033025 is 74.2% identical to Applicants' SEQ ID NO : 1 and encodes a protein Q9UIM1 which is 74.4% identical to Applicants' SEQ ID NO : 2].	1-24



Further documents are listed in the continuation of Box C.



See patent family annex.

Special categories of cited documents:	
*A* document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*E* earlier application or patent published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*O* document referring to an oral disclosure, use, exhibition or other means	*Z* document member of the same patent family
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 10 March 2003 (10.03.2003)	Date of mailing of the international search report 21 APR 2003
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230	Authorized officer Tekchand Saidha Telephone No. (703) 308-0196

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
13 February 2003 (13.02.2003)

PCT

(10) International Publication Number  
WO 03/012070 A2

(51) International Patent Classification<sup>7</sup>: C12N

(21) International Application Number: PCT/US02/24764

(22) International Filing Date: 5 August 2002 (05.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/309,495 3 August 2001 (03.08.2001) US  
60/317,975 10 September 2001 (10.09.2001) US

(71) Applicants (for all designated States except US): GENE LOGIC, INC. [US/US]; 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). THE PROCTER & GAMBLE COMPANY [US/US]; Health Care Research Center, Box 1057, 8700 Mason Montgomery Road, Mason, OH 45040-9462 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): JAISWAL, Neelam [US/US]; The Procter & Gamble Company, Health Care Research Center, Box 1057, 8700 Mason Montgomery Road, Mason, OH 45040-9462 (US). HOUGHTON, Adam [US/US]; The Procter & Gamble Company, Health Care Research Center, Box 1057, 8700 Mason Montgomery Road, Mason, OH 45040-9462 (US). MERTZ, Lawrence [US/US]; 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). JI, Darren [US/US]; The Procter & Gamble Company, Health Care Research Center, Box 1057, 8700 Mason Montgomery Road, Mason, OH 45040-9462 (US). COOK, Jonathan, S. [US/US]; The

Procter & Gamble Company, Health Care Research Center, Box 1057, 8700 Mason Montgomery Road, Mason, OH 45040-9462 (US). AXELROD, Douglas, W. [US/US]; The Procter & Gamble Company, Health Care Research Center, Box 1057, 8700 Mason Montgomery Road, Mason, OH 45040-9462 (US).

(74) Agents: SMYTH, Robert, J. et al.; Morgan, Lewis & Bockius LLP, 1111 Pennsylvania Avenue, NW, Washington, DC 20004 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GENE ASSOCIATED WITH BONE DISORDERS

(57) Abstract: The present invention relates to identifying genes that are differentially regulated or expressed in bone deposition disorders. Specifically, a novel gene has been identified as being differentially regulated during the maturation of osteoblasts and whose expression can be correlated, for example, with bone deposition disorders such as osteoporosis (including correlation with degrees of severity of the disease).



WO 03/012070 A2

## GENE ASSOCIATED WITH BONE DISORDERS

### RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Applications 60/309,495 (filed August 3, 2001) and 60/317,975 (filed September 10, 2001); all of which are herein incorporated by reference in their entirety.

### BACKGROUND OF THE INVENTION

Living bone tissue is continuously being replenished by the processes of resorption and deposition of bone matrix and minerals. This temporally and spatially coupled process, termed bone remodeling, is accomplished largely by two cell populations, osteoclasts and osteoblasts. The remodeling process is initiated when osteoclasts are recruited from the bone marrow or the circulation to the bone surface to remove a disk-shaped packet of bone producing an area of resorbed surface. A team of osteoblasts recruited to the resorbed bone surface from the bone marrow subsequently replaces the bone matrix and mineral. Among the pathological conditions associated with abnormal bone cell function is osteoporosis, a disease characterized by reduced amounts of bone (osteopenia) and increased bone fragility. These changes can be the result of increased recruitment and activity of osteoclasts, in combination with reduced recruitment or activity of osteoblasts (Teitelbaum *et al.* (1997) *J. Leukoc. Biol.* 61, 381-388; Simonet *et al.* (1997) *Cell* 89, 309-319).

A very significant patient population that would benefit from new therapies designed to promote bone formation or inhibit resorption are those patients suffering from osteoporosis. Clinically, osteoporosis is segregated into type I and type II. Type I osteoporosis occurs predominantly in middle aged women and is associated with estrogen loss at menopause, while osteoporosis type II is associated with advancing age. An estimated twenty to twenty-five million people are at increased risk for fracture because of site-specific bone loss. The cost of treating osteoporosis in the United States is currently estimated to be in the order of ten billion dollars per year. Demographic trends, *i.e.*, the gradually increasing age of the United States population, suggest that these costs may increase up to three fold by the year 2020 if a safe and effective treatment is not found.

Bone resorption is initiated with the destruction of bone matrix by osteoclasts. Following this initial phase of bone destruction, or resorptive phase, formation of new bone protein matrix begins. New bone proteins are deposited, and sometime later, minerals begin to be incorporated into the newly formed matrix. The formation of bone matrix and its subsequent mineralization are exclusive functions of osteoblasts.

In theory, either decreased bone formation relative to resorption or increased bone resorption relative to formation can cause the net loss of bone in osteoporosis. Control of the rate of breakdown and synthesis of new bone tissue is critical to the integrity of the skeletal structure.

When the rates become unbalanced, serious conditions may result. Although there is always a net excess of bone resorption in osteoporosis, the absolute amounts of bone formation and resorption can vary from case to case.

## SUMMARY OF THE INVENTION

Few treatments are available to modulate the formation and resorption processes of bone maintenance and development. In bone disorders such as osteoporosis, it may be useful to monitor or modify the expression levels or activities of genes involved in bone formation or resorption. The present inventors have examined cell populations comprising precursor stem cells and cell populations comprising precursor stem cells that have been induced to differentiate into osteoblasts and have discovered that the expression of previously unidentified gene changes during this differentiation process. This change in gene expression provides a useful marker for diagnostic and prognostic uses as well as a marker that can be used for drug screening and therapeutic indications.

The invention encompasses an isolated nucleic acid molecule selected from the group consisting of: an isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1; an isolated nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2; an isolated nucleic acid molecule that encodes a polypeptide fragment of at least about 1,015 amino acids of SEQ ID NO: 2; and an isolated nucleic acid molecule that encodes a polypeptide that exhibits at least about 75% amino acid sequence identity to SEQ ID NO: 2 over the entire contiguous sequence. In a preferred embodiment of the invention, the isolated nucleic acid comprises nucleotides 251-4,336 of SEQ ID NO: 1.

In some embodiments, the isolated nucleic acid molecule is operably linked to one or more expression control elements. The invention also includes a vector comprising an isolated nucleic acid molecule and a host cell transformed to contain the nucleic acid molecule. The host cell may be either eukaryotic or prokaryotic.

The invention also encompasses a method for producing a polypeptide comprising culturing a host cell transformed with the aforementioned nucleic acid molecule under conditions in which the polypeptide encoded by said nucleic acid molecule is expressed and the isolated polypeptide produced by this method.

The invention further encompasses an isolated polypeptide selected from the group consisting of: an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 2; an

isolated polypeptide comprising a fragment of at least 1,015 amino acids of SEQ ID NO: 2; an isolated polypeptide comprising conservative amino acid substitutions of SEQ ID NO: 2; and an isolated polypeptide exhibiting at least about 75% amino acid sequence identity with SEQ ID NO: 2. In some embodiments, the isolated polypeptide comprises amino acids 1 to 348 of SEQ ID NO: 2. The invention includes isolated antibodies that bind to the aforementioned polypeptide. The antibodies may be either monoclonal or polyclonal.

The invention encompasses a method of screening for an agent that modulates the differentiation of a population of stem cells into osteoblast cells or is capable of increasing bone density comprising: exposing a population of stem cells to the agent, and measuring expression or activity of a polypeptide encoded by the nucleic acid of the invention following exposure to the agent, wherein an decrease in the level of expression or activity is indicative of an agent capable of stimulating stem cells to differentiate into osteoblast cells or increasing bone density.

In yet another embodiment, the invention includes a method of diagnosing a condition characterized by abnormal stem cell differentiation or bone density comprising detecting in a stem cell sample the level of expression or activity of a polypeptide encoded by the nucleic acid of the invention, wherein abnormal expression or activity is indicative of a condition characterized by abnormal stem cell differentiation or bone cell density. In a preferred embodiment, the condition is osteoporosis.

## **20 BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 provides a graphical representation of the expression level of the target mRNA of SEQ ID NO: 1 in human fetal stromal cells as assayed using READS gel analysis in response to treatment with the osteogenic agent TGF- $\beta$ 1 (1 ng/ml) versus untreated controls. Figure 1A shows the effect over a time period of twenty-four days whereas Figure 1B shows effects over a period of forty-eight hours.

Figure 2 provides a graphical representation of the expression level of the target mRNA of SEQ ID NO: 1 in human fetal stromal cells assayed using READS gel analysis in response to treatment with the osteogenic agent BMP-2 (300 ng/ml) versus untreated controls. Figure 2A shows the effect over a time period of twenty-four days whereas Figure 2B shows effects over a period of forty-eight hours.

Figure 3 provides a graphical representation of the expression level of the target mRNA of SEQ ID NO: 1 in human mesenchymal stem cells as assayed using READS gel analysis in response to treatment with osteogenic and adipogenic agents. In Figure 3A, cells were cultured in a medium supplemented with 10% fetal calf serum with or without dexamethasone (100 nM) for time period ranging from zero to seven days. In Figure 3B, cells were cultured in the same

manner with or without BMP-2 (200 ng/ml) for the same time period. In Figure 3C, cells were cultured in a medium containing 10% rabbit serum with or without addition of dexamethasone (100 nM) for the same time period.

Figure 4 provides a graphical representation of the expression levels of the target mRNA of SEQ ID NO: 1 in human fetal stromal cells (A, B) and in human mesenchymal stromal cells (C) as assayed by quantitative RT-PCR. In Figure 4A, cells were cultured using non-mineralization conditions in the absence (control, open circles with dotted line) or presence of either 1 ng/ml TGF- $\beta$ 1 (closed circles) or 300 ng/ml of BMP-2 (closed triangles) for time periods up to six days. In Figure 4B, cells were cultured using mineralization conditions in the absence of the same agents as in Figure 4A for time periods up to twenty-one days (504 hours). In Figure 4C, mesenchymal stem cells were cultured in media supplemented with ascorbic acid and  $\beta$ -glycerophosphate in the absence and presence of either 1 ng/ml TGF- $\beta$ 1, 200 ng/ml BMP-2 or 100 nM dexamethasone for time periods up to sixteen days (384 hours).

Figure 5 shows expression levels, depicted as Ct values, of the target mRNA of SEQ ID NO: 1 in various human tissues as assayed using TaqMan quantitative RT-PCR methods. Expression levels of the target mRNA in resting human fetal stromal cells (HFSC control) and human mesenchymal stem cells (MSC control) is also provided.

Figure 6 displays a graphical representation of the results of a hydrophobicity analysis of the polypeptide of SEQ ID NO: 2.

Figure 7 shows a Northern blot in which the expression level of SEQ ID NO: 1 was measured in several normal human tissues including brain, heart, skeletal muscle, colon, thymus, spleen, kidney, liver, small intestine, placenta, lung and in leukocytes (ClonTech human mRNA blot-H12). RNA markers are present on the left side of the blot.

Figure 8 shows a Northern blot in which the expression level of SEQ ID NO: 1 was measured in human tissues as well as in human fetal stromal cells (FSC) and mesenchymal stem cells (MSC) treated with control or osteogenic agents.

Figure 9 provides a graphical representation of the effects of inhibition of target mRNA expression on osteoblast differentiation, as measured by alkaline phosphatase expression. In Figure 9A treatment of 100 ng/ml BMP-2 treated cells with siRNA duplex increases alkaline phosphatase expression by 414% compared to control duplex treated cells. Figure 9B demonstrates that the inhibition of target mRNA expression by the same siRNA duplex was 73% compared to control duplex.

## DETAILED DESCRIPTION

### General Description

The present invention is based in part on the identification of a new gene family that is differentially expressed in bone deposition disorders. This gene, designated 76032, corresponds to the human cDNA of SEQ ID NO: 1. Genes that encode the human protein of SEQ ID NO: 2 may also be found in other animal species, particularly mammalian species. This novel gene has been identified as being differentially regulated during the maturation of osteoblasts and its expression is correlated, for example, with bone deposition disorders such as osteoporosis.

Further, monitoring of expression may be used for disease diagnosis and may be indicative of treatment efficacy. The nucleic acid molecules of SEQ ID NO: 1 or its fragments, as well as the peptides they encode, can serve as targets for agents that can be used to modulate the activity of the proteins and nucleic acids of the invention, such as the protein having the amino acid sequence of SEQ ID NO: 2. For example, agents may be identified which bind to the proteins and nucleic acids of the invention and modulate biological processes associated with bone deposition such as differentiation of stem cells into osteoblasts.

### Definitions

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described.

As used herein, the term "bone density" refers to the mass or quantity of bone tissue in a certain volume of bone.

As used herein, the term "bone deposition" refers the formation of new bone during osteogenesis.

As used herein, the term "bone resorption" refers to a decrease in bone density and/or mass. Generally, mechanisms of bone resorption include, but are not limited to, secretion of enzymes and/or acids by osteoclasts to facilitate the breakdown of bone.

As used herein, the term "osteoporosis" refers to a pathological disorder characterized by a reduction in the amount of bone mass and/or density. Osteoporosis is generally characterized by increased osteoclast activity and/or decreased osteoblast activity.

As used herein, the term "stem cell" or "mesenchymal stem cell" refers to a cell capable of differentiation into an osteoblast cell. These terms are used interchangeably throughout the specification to indicate that the cell is undifferentiated.



As used herein, the terms "stem cell differentiation" and "osteoblast differentiation" refers to the process in which a stem cell develops specialized functions during maturation into an osteoblast cell.

As used herein, the term "osteoblast" refers to a cell capable of mediating bone deposition. Osteoblasts are derived from mesenchymal stem cells of the bone marrow stroma.

As used herein, the term "osteoclast" refers to a cell capable of mediating bone resorption.

### Nucleic Acid Molecules

10 The present invention further provides nucleic acid molecules that encode the protein having SEQ ID NO: 2 and the related proteins herein described, preferably in isolated form. As used herein, "nucleic acid" is defined as RNA or DNA that encodes a protein or peptide as defined above, is complementary to a nucleic acid sequence encoding such peptides, hybridizes to SEQ ID NO: 1 across the open reading frame under appropriate stringency conditions, or  
15 encodes a polypeptide that shares at least about 75% sequence identity, preferably at least about 80%, more preferably at least about 85%, and even more preferably at least about 90% or even 95% or more identity with the entire contiguous amino acid sequence of SEQ ID NO: 2. The "nucleic acid" of the invention further includes nucleic acid molecules that share at least 80%, preferably at least about 85%, and more preferably at least about 90% or 95% or more identity  
20 with the nucleotide sequence of SEQ ID NO: 1, particularly across the open reading frame. Specifically contemplated are genomic DNA, cDNA, mRNA and antisense molecules, as well as nucleic acids based on alternative backbones or including alternative bases whether derived from natural sources or synthesized. Such nucleic acids, however, are defined further as being novel and unobvious over any prior art nucleic acid including that which encodes, hybridizes under  
25 appropriate stringency conditions, or is complementary to nucleic acid encoding a protein according to the present invention.

Homology or identity at the nucleotide or amino acid sequence level is determined by BLAST (Basic Local Alignment Search Tool) analysis using the algorithm employed by the programs blastp, blastn, blastx, tblastn and tblastx (Altschul *et al.* (1997) Nucleic Acids Res.  
30 25, 3389-3402 and Karlin *et al.* (1990) Proc. Natl. Acad. Sci. USA 87, 2264-2268, both fully incorporated by reference) which are tailored for sequence similarity searching. The approach used by the BLAST program is to first consider similar segments, with and without gaps, between a query sequence and a database sequence, then to evaluate the statistical significance of all matches that are identified and finally to summarize only those matches which satisfy a  
35 preselected threshold of significance. For a discussion of basic issues in similarity searching of

sequence databases, see Altschul *et al.* (1994) *Nature Genetics* 6, 119-129 which is fully incorporated by reference. The search parameters for histogram, descriptions, alignments, expect (*i.e.*, the statistical significance threshold for reporting matches against database sequences), cutoff, matrix and filter (low complexity) are at the default settings. The default scoring matrix used by blastp, blastx, tblastn, and tblastx is the BLOSUM62 matrix (Henikoff *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89, 10915-10919, fully incorporated by reference), recommended for query sequences over 85 in length (nucleotide bases or amino acids).

For blastn, the scoring matrix is set by the ratios of M (*i.e.*, the reward score for a pair of matching residues) to N (*i.e.*, the penalty score for mismatching residues), wherein the default values for M and N are +5 and -4, respectively. Four blastn parameters were adjusted as follows: Q=10 (gap creation penalty); R=10 (gap extension penalty); wink=1 (generates word hits at every wink<sup>th</sup> position along the query); and gapw=16 (sets the window width within which gapped alignments are generated). The equivalent Blastp parameter settings were Q=9; R=2; wink=1; and gapw=32. A Bestfit comparison between sequences, available in the GCG package version 10.0, uses DNA parameters GAP=50 (gap creation penalty) and LEN=3 (gap extension penalty) and the equivalent settings in protein comparisons are GAP=8 and LEN=2.

"Stringent conditions" are those that (1) employ low ionic strength and high temperature for washing, for example, 0.015 M NaCl/0.0015 M sodium citrate/0.1% SDS at 50°C, or (2) employ during hybridization a denaturing agent such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer (pH 6.5) with 750 mM NaCl, 75 mM sodium citrate at 42°C. Another example is hybridization in 50% formamide, 5× SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5× Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2× SSC and 0.1% SDS. A skilled artisan can readily determine and vary the stringency conditions appropriately to obtain a clear and detectable hybridization signal. Preferred molecules are those that hybridize under the above conditions to the complement of SEQ ID NO: 1 and which encode a functional protein. Even more preferred hybridizing molecules are those that hybridize under the above conditions to the complement strand of the open reading frame of SEQ ID NO: 1.

As used herein, a nucleic acid molecule is said to be "isolated" when the nucleic acid molecule is substantially separated from contaminant nucleic acid molecules encoding other polypeptides.

The present invention further provides fragments of the encoding nucleic acid molecule. As used herein, a fragment of an encoding nucleic acid molecule refers to a small portion of the

entire protein coding sequence. The size of the fragment will be determined by the intended use. For example, if the fragment is chosen so as to encode an active portion of the protein, the fragment will need to be large enough to encode the functional regions of the protein. For instance, fragments which encode peptides corresponding to predicted antigenic regions may be prepared. If the fragment is to be used as a nucleic acid probe or PCR primer, then the fragment length is chosen so as to obtain a relatively small number of false positives during probing/priming.

Fragments of the encoding nucleic acid molecules of the present invention (*i.e.*, synthetic oligonucleotides) that are used as probes or specific primers for the polymerase chain reaction (PCR), or to synthesize gene sequences encoding proteins of the invention, can easily be synthesized by chemical techniques, for example, the phosphotriester method of Matteucci *et al.* (1981) J. Am. Chem. Soc. 103, 3185-3191 or using automated synthesis methods. In addition, larger DNA segments can readily be prepared by well known methods, such as synthesis of a group of oligonucleotides that define various modular segments of the gene, followed by ligation of oligonucleotides to build the complete modified gene. In a preferred embodiment, the nucleic acid molecule of the present invention contains a contiguous open reading frame of at least about three-thousand and forty-five nucleotides.

The encoding nucleic acid molecules of the present invention may further be modified so as to contain a detectable label for diagnostic and probe purposes. A variety of such labels are known in the art and can readily be employed with the encoding molecules herein described. Suitable labels include, but are not limited to, biotin, radiolabeled nucleotides and the like. A skilled artisan can readily employ any such label to obtain labeled variants of the nucleic acid molecules of the invention. Modifications to the primary structure itself by deletion, addition, or alteration of the amino acids incorporated into the protein sequence during translation can be made without destroying the activity of the protein. Such substitutions or other alterations result in proteins having an amino acid sequence encoded by a nucleic acid falling within the contemplated scope of the present invention.

#### **Isolation of Other Related Nucleic Acid Molecules**

As described above, the identification and characterization of the nucleic acid molecule having SEQ ID NO: 1 allows a skilled artisan to isolate nucleic acid molecules that encode other members of the protein family in addition to the sequences herein described.

For instance, a skilled artisan can readily use the amino acid sequence of SEQ ID NO: 2 to generate antibody probes to screen expression libraries prepared from appropriate cells.

Typically, polyclonal antiserum from mammals such as rabbits immunized with the purified

protein (as described below) or monoclonal antibodies can be used to probe a mammalian cDNA or genomic expression library, such as lambda gtl library, to obtain the appropriate coding sequence for other members of the protein family. The cloned cDNA sequence can be expressed as a fusion protein, expressed directly using its own control sequences, or expressed by constructions using control sequences appropriate to the particular host used for expression of the enzyme.

Alternatively, a portion of the coding sequence herein described can be synthesized and used as a probe to retrieve DNA encoding a member of the protein family from any mammalian organism. Oligomers containing approximately 18-20 nucleotides (encoding about a 6-7 amino acid stretch) are prepared and used to screen genomic DNA or cDNA libraries to obtain hybridization under stringent conditions or conditions of sufficient stringency to eliminate an undue level of false positives.

Additionally, pairs of oligonucleotide primers can be prepared for use in a polymerase chain reaction (PCR) to selectively clone an encoding nucleic acid molecule. A PCR denature/anneal/extend cycle for using such PCR primers is well known in the art and can readily be adapted for use in isolating other encoding nucleic acid molecules.

Nucleic acid molecules encoding other members of the protein family may also be identified in existing genomic or other sequence information using any available computational method, including but not limited to: PSI-BLAST (Altschul *et al.* (1997) *Nucleic Acids Res.* 25:3389-3402); PHI-BLAST (Zhang *et al.* (1998), *Nucleic Acids Res.* 26, 3986-3990), 3D-PSSM (Kelly *et al.* (2000) *J. Mol. Biol.* 299, 499-520); and other computational analysis methods (Shi *et al.* (1999) *Biochem. Biophys. Res. Commun.* 262, 132-138 and Matsunami *et al.* (2000) *Nature* 404, 601-604).

## **Recombinant DNA molecules Containing a Nucleic Acid Molecule**

The present invention further provides recombinant DNA molecules (rDNAs) that contain a coding sequence. As used herein, a rDNA molecule is a DNA molecule that has been subjected to molecular manipulation *in situ*. Methods for generating rDNA molecules are well known in the art, for example, see Sambrook *et al.* (1989) *Molecular Cloning - A Laboratory Manual*, Cold Spring Harbor Laboratory Press. In the preferred rDNA molecules, a coding DNA sequence is operably linked to expression control sequences and/or vector sequences.

The choice of vector and/or expression control sequences to which one of the protein family encoding sequences of the present invention is operably linked depends directly, as is well known in the art, on the functional properties desired, e.g., protein expression, and the host cell to be transformed. A vector contemplated by the present invention is at least capable of

directing the replication or insertion into the host chromosome, and preferably also expression, of the structural gene included in the rDNA molecule.

Expression control elements that are used for regulating the expression of an operably linked protein encoding sequence are known in the art and include, but are not limited to, inducible promoters, constitutive promoters, secretion signals, and other regulatory elements. Preferably, the inducible promoter is readily controlled, such as being responsive to a nutrient in the host cell's medium.

In one embodiment, the vector containing a coding nucleic acid molecule will include a prokaryotic replicon, *i.e.*, a DNA sequence having the ability to direct autonomous replication and maintenance of the recombinant DNA molecule extrachromosomally in a prokaryotic host cell, such as a bacterial host cell, transformed therewith. Such replicons are well known in the art. In addition, vectors that include a prokaryotic replicon may also include a gene whose expression confers a detectable marker such as a drug resistance. Typical bacterial drug resistance genes are those that confer resistance to ampicillin or tetracycline.

Vectors that include a prokaryotic replicon can further include a prokaryotic or bacteriophage promoter capable of directing the expression (transcription and translation) of the coding gene sequences in a bacterial host cell, such as *E. coli*. A promoter is an expression control element formed by a DNA sequence that permits binding of RNA polymerase and transcription to occur. Promoter sequences compatible with bacterial hosts are typically provided in plasmid vectors containing convenient restriction sites for insertion of a DNA segment of the present invention. Typical of such vector plasmids are pUC8, pUC9, pBR322 and pBR329 (BioRad), pPL and pKK223 (Pharmacia).

Expression vectors compatible with eukaryotic cells, preferably those compatible with vertebrate cells, can also be used to form rDNA molecules that contain a coding sequence. Eukaryotic cell expression vectors, including viral vectors, are well known in the art and are available from several commercial sources. Typically, such vectors are provided containing convenient restriction sites for insertion of the desired DNA segment. Typical of such vectors are pSVL and pKSV-10 (Pharmacia), pBPV-1/pML2d (International Biotechnologies, Inc.), pTDT1 (ATCC), the vector pCDM8 described herein, and the like eukaryotic expression vectors.

Eukaryotic cell expression vectors used to construct the rDNA molecules of the present invention may further include a selectable marker that is effective in an eukaryotic cell, preferably a drug resistance selection marker. A preferred drug resistance marker is the gene whose expression results in neomycin resistance, *i.e.*, the neomycin phosphotransferase (*neo*) gene. (Southern *et al.* (1982) J. Mol. Anal. Genet. 1, 327-341). Alternatively, the selectable

marker can be present on a separate plasmid, and the two vectors are introduced by co-transfection of the host cell, and selected by culturing in the appropriate drug for the selectable marker. The present invention further provides host cells transformed with a nucleic acid molecule that encodes a protein of the present invention. The host cell can be either prokaryotic or eukaryotic. Eukaryotic cells useful for expression of a protein of the invention are not limited, so long as the cell line is compatible with cell culture methods and compatible with the propagation of the expression vector and expression of the gene product. Preferred eukaryotic host cells include, but are not limited to, yeast, insect and mammalian cells, preferably vertebrate cells such as those from a mouse, rat, monkey or human cell line. Preferred eukaryotic host cells include Chinese hamster ovary (CHO) cells available from the ATCC as CCL61, NIH Swiss mouse embryo cells (NIH-3T3) available from the ATCC as CRL 1658, baby hamster kidney cells (BHK), and the like eukaryotic tissue culture cell lines.

Any prokaryotic host can be used to express a rDNA molecule encoding a protein of the invention. The preferred prokaryotic host is *E. coli*.

Transformation of appropriate cell hosts with a rDNA molecule of the present invention is accomplished by well known methods that typically depend on the type of vector used and host system employed. With regard to transformation of prokaryotic host cells, electroporation and salt treatment methods are typically employed, see, for example, Cohen *et al.* (1972) Proc. Natl. Acad. Sci. USA 69, 2110; and Sambrook *et al.* (1989) Molecular Cloning - A Laboratory Manual, Cold Spring Harbor Laboratory Press. With regard to transformation of vertebrate cells with vectors containing rDNAs, electroporation, cationic lipid or salt treatment methods are typically employed, see, for example, Graham *et al.* (1973) Virology 52, 456; Wigler *et al.* (1979) Proc. Natl. Acad. Sci. USA 76, 1373-1376.

Successfully transformed cells, *i.e.*, cells that contain a rDNA molecule of the present invention, can be identified by well known techniques including the selection for a selectable marker. For example, cells resulting from the introduction of an rDNA of the present invention can be cloned to produce single colonies. Cells from those colonies can be harvested, lysed and their DNA content examined for the presence of the rDNA using a method such as that described by Southern (1975) J. Mol. Biol. 98, 503-504 or Berent *et al.* (1985) Biotech. 3, 208-209 or the proteins produced from the cell assayed via an immunological method.

#### **Production of Recombinant Proteins using a rDNA Molecule**

The present invention further provides methods for producing a protein of the invention using nucleic acid molecules herein described. In general terms, the production of a recombinant form of a protein typically involves the following steps:

A nucleic acid molecule is first obtained that encodes a protein of the invention, such as a nucleic acid molecule comprising, consisting essentially of or consisting of SEQ ID NO: 1 or nucleotides 251-4336 of SEQ ID NO: 1. If the encoding sequence is uninterrupted by introns, as is this open reading frame, it is directly suitable for expression in any host.

5       The nucleic acid molecule is then preferably placed in operable linkage with suitable control sequences, as described above, to form an expression unit containing the protein open reading frame. The expression unit is used to transform a suitable host and the transformed host is cultured under conditions that allow the production of the recombinant protein. Optionally the recombinant protein is isolated from the medium or from the cells; recovery and purification  
10   of the protein may not be necessary in some instances where some impurities may be tolerated.

Each of the foregoing steps can be done in a variety of ways. For example, the desired coding sequences may be obtained from genomic fragments and used directly in appropriate hosts. The construction of expression vectors that are operable in a variety of hosts is accomplished using appropriate replicons and control sequences, as set forth above. The control  
15   sequences, expression vectors, and transformation methods are dependent on the type of host cell used to express the gene and were discussed in detail earlier. Suitable restriction sites can, if not normally available, be added to the ends of the coding sequence so as to provide an excisable gene to insert into these vectors. A skilled artisan can readily adapt any host/expression system known in the art for use with the nucleic acid molecules of the invention  
20   to produce recombinant protein.

#### **The Protein Associated with Bone Disorders**

The present invention provides isolated proteins, allelic variants of the proteins, and conservative amino acid substitutions of the protein comprising the amino acids sequence of  
25   SEQ ID NO: 2. As used herein, the "protein" or "polypeptide" refers, in part, to a protein that has the human amino acid sequence depicted in SEQ ID NO: 2. The terms also refer to naturally occurring allelic variants and proteins that have a slightly different amino acid sequence than that specifically recited above. Allelic variants, though possessing a slightly different amino acid sequence than those recited above, will still have the same or similar biological functions  
30   associated with these proteins.

As used herein, the family of proteins related to the human amino acid sequences of SEQ ID NO: 2 refers to proteins that have been isolated from organisms in addition to humans. The methods used to identify and isolate other members of the family of proteins related to these proteins are described below.

The proteins of the present invention are preferably in isolated form. As used herein, a protein is said to be isolated when physical, mechanical or chemical methods are employed to remove the protein from cellular constituents that are normally associated with the protein. A skilled artisan can readily employ standard purification methods to obtain an isolated protein.

5       The proteins of the present invention further include insertion, deletion or conservative amino acid substitution variants of SEQ ID NO: 2. As used herein, a conservative variant refers to alterations in the amino acid sequence that does not adversely affect the biological functions of the protein. A substitution, insertion or deletion is said to adversely affect the protein when the altered sequence prevents or disrupts a biological function associated with the protein. For  
10       example, the overall charge, structure or hydrophobic/hydrophilic properties of the protein can be altered without adversely affecting a biological activity. Accordingly, the amino acid sequence can be altered, for example to render the peptide more hydrophobic or hydrophilic, without adversely affecting the biological activities of the protein.

Ordinarily, the allelic variants, the conservative substitution variants, and the members  
15       of the protein family, will have an amino acid sequence having at least about 75% amino acid sequence identity with the entire sequence set forth in SEQ ID NO: 2, more preferably at least about 80%, even more preferably at least about 90%, and most preferably at least about 95% sequence identity. Identity or homology with respect to such sequences is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the known  
20       peptides, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity. Fusion proteins, or N-terminal, C-terminal or internal extensions, deletions, or insertions into the peptide sequence shall not be construed as affecting homology.

Thus, the proteins of the present invention include molecules having the amino acid  
25       sequence disclosed in SEQ ID NO: 2 and fragments thereof having a consecutive sequence of at least about 1015 or more amino acid residues of these proteins; amino acid sequence variants wherein one or more amino acid residues has been inserted N- or C-terminal to, or within, the disclosed coding sequence; and amino acid sequence variants of the disclosed sequence, or their fragments as defined above, that have been substituted by at least one residue. Such fragments,  
30       also referred to as peptides or polypeptides, may contain antigenic regions, functional regions of the protein identified as regions of the amino acid sequence which correspond to known protein domains, as well as regions of pronounced hydrophilicity. The regions are all easily identifiable by using commonly available protein sequence analysis software such as MacVector (Oxford Molecular).

35       Contemplated variants further include those containing predetermined mutations by,



e.g., homologous recombination, site-directed or PCR mutagenesis, and the corresponding proteins of other animal species, including but not limited to rabbit, mouse, rat, porcine, bovine, ovine, equine and non-human primate species, and the alleles or other naturally occurring variants of the family of proteins; and derivatives wherein the protein has been covalently modified by substitution, chemical, enzymatic, or other appropriate means with a moiety other than a naturally occurring amino acid (for example a detectable moiety such as an enzyme or radioisotope).

The present invention further provides compositions comprising a protein or polypeptide of the invention and a diluent. Suitable diluents can be aqueous or non-aqueous solvents or a combination thereof, and can comprise additional components, for example water-soluble salts or glycerol, that contribute to the stability, solubility, activity, and/or storage of the protein or polypeptide.

As described below, members of the family of proteins can be used: (1) to identify agents which modulate the level of or at least one activity of the protein, (2) to identify binding partners for the protein, (3) as an antigen to raise polyclonal or monoclonal antibodies, (4) as a therapeutic agent or target and (5) as a diagnostic agent or marker of osteoporosis and other bone disorders.

#### **Methods to Identify Binding Partners**

Another embodiment of the present invention provides methods for use in isolating and identifying binding partners of proteins of the invention. In general, a protein of the invention is mixed with a potential binding partner or an extract or fraction of a cell under conditions that allow the association of potential binding partners with the protein of the invention. After mixing, peptides, polypeptides, proteins or other molecules that have become associated with a protein of the invention are separated from the mixture. The binding partner that bound to the protein of the invention can then be removed and further analyzed. To identify and isolate a binding partner, the entire protein, for instance a protein comprising the entire amino acid sequence of SEQ ID NO: 2 can be used. Alternatively, a fragment of the protein can be used.

As used herein, a cellular extract refers to a preparation or fraction that is made from a lysed or disrupted cell. The preferred source of cellular extracts will be cells derived from human skin tissue or the human respiratory tract or cells derived from a biopsy sample of human lung tissue in patients with allergic hypersensitivity. Alternatively, cellular extracts may be prepared from normal tissue or available cell lines, particularly granulocytic cell lines.

A variety of methods can be used to obtain an extract of a cell. Cells can be disrupted using either physical or chemical disruption methods. Examples of physical disruption methods

include, but are not limited to, sonication and mechanical shearing. Examples of chemical lysis methods include, but are not limited to, detergent lysis and enzyme lysis. A skilled artisan can readily adapt methods for preparing cellular extracts in order to obtain extracts for use in the present methods.

5        Once an extract of a cell is prepared, the extract is mixed with the protein of the invention under conditions in which association of the protein with the binding partner can occur. A variety of conditions can be used, the most preferred being conditions that closely resemble conditions found in the cytoplasm of a human cell. Features such as osmolarity, pH, temperature, and the concentration of cellular extract used, can be varied to optimize the  
10       association of the protein with the binding partner.

      After mixing under appropriate conditions, the bound complex is separated from the mixture. A variety of techniques can be utilized to separate the mixture. For example, antibodies specific to a protein of the invention can be used to immunoprecipitate the binding partner complex. Alternatively, standard chemical separation techniques such as  
15       chromatography and density/sediment centrifugation can be used.

      After removal of non-associated cellular constituents found in the extract, the binding partner can be dissociated from the complex using conventional methods. For example, dissociation can be accomplished by altering the salt concentration or pH of the mixture. To aid in separating associated binding partner pairs from the mixed extract, the protein of the  
20       invention can be immobilized on a solid support. For example, the protein can be attached to a nitrocellulose matrix or acrylic beads. Attachment of the protein to a solid support aids in separating peptide/binding partner pairs from other constituents found in the extract. The identified binding partners can be either a single protein or a complex made up of two or more proteins. Alternatively, binding partners may be identified using a Far-Western assay according  
25       to the procedures of Takayama *et al.* (1997) *Methods Mol. Biol.* 69, 171-184 or Sauder *et al.* (1996) *J. Gen. Virol.* 77, 991-996 or identified through the use of epitope tagged proteins or GST fusion proteins.

      Alternatively, the nucleic acid molecules of the invention can be used in a yeast two-hybrid system. The yeast two-hybrid system has been used to identify other protein partner pairs  
30       and can readily be adapted to employ the nucleic acid molecules herein described.

#### **Modulation of Expression**

      The present inventors have identified the proteins of the invention as being associated with mesenchymal stem cell differentiation and subsequent osteoblast activity. Specifically, the expression and activation of the proteins of the invention, such as the protein having the amino  
35       acid sequence of SEQ ID NO: 2, in mesenchymal stem cells correlated with the maturation of

these cells into osteoblasts and subsequent deposition of bone. The present invention therefore includes methods for modulating expression and/or activity of the proteins of the invention to effect mesenchymal stem cell differentiation and osteoblast activity. Such methods will be useful in the treatment of disorders associated with abnormal osteoblast activity. Because  
5 osteoblast activity indirectly effects osteoclast activity via a general feedback mechanism, the invention also includes methods for modulating bone resorption associated with osteoclast activity.

Modulation of the gene, gene fragments, or the encoded protein of SEQ ID NO: 2 and fragments is useful in gene therapy to treat disorders associated with defects in the protein of the  
10 invention. In a preferred embodiment, expression is modulated to increase osteoblast activity in diseases with abnormal bone density. Expression vectors may be used to introduce the nucleic acids of the invention into a cell. Such vectors generally have convenient restriction sites located near the promoter sequence to provide for the insertion of nucleic acid sequences. Transcription cassettes may be prepared comprising a transcription initiation region, the target  
15 gene or fragment thereof, and a transcriptional termination region. The transcription cassettes may be introduced into a variety of vectors, e.g., plasmid, retrovirus, lentivirus, adenovirus and the like, where the vectors are able to transiently or stably be maintained in the cells, usually for a period of at least about one day, more usually for a period of at least about several days to several weeks.

The proteins and nucleic acids of the invention may be introduced into tissues or host  
20 cells by any number of routes, including viral infection, microinjection, or fusion of vesicles. Jet injection may also be used for intramuscular administration, as described by Furth *et al.* (1992) Anal. Biochem. 205, 365-368. The DNA may be coated onto gold microparticles, and delivered intradermally by a particle bombardment device, or "gene gun" as described in the literature  
25 (see, for example, Tang *et al.* (1992) Nature 356, 152-154), where gold microprojectiles are coated with DNA, then bombarded into skin cells.

Antisense molecules can be used to down-regulate expression of nucleic acids or proteins of the invention in cells. The anti-sense reagent may be antisense oligonucleotides, particularly synthetic antisense oligonucleotides having chemical modifications from native  
30 nucleic acids, or nucleic acid constructs that express such anti-sense molecules as RNA. The antisense sequence is complementary to the mRNA of the targeted gene, and inhibits expression of the targeted gene products. Antisense molecules inhibit gene expression through various mechanisms, e.g., by reducing the amount of mRNA available for translation, through activation of RNase H or steric hindrance. One or a combination of antisense molecules may be  
35 administered, where a combination may comprise multiple different sequences.

Antisense molecules may be produced by expression of all or a part of the target gene sequence in an appropriate vector, where the transcriptional initiation is oriented such that an antisense strand is produced as an RNA molecule. Alternatively, the antisense molecule is a synthetic oligonucleotide. Antisense oligonucleotides will generally be at least about seven,  
5 usually at least about twelve, and more usually at least about twenty nucleotides in length. Typical antisense oligonucleotides are usually not more than about five-hundred, more usually not more than about fifty, and even more usually not more than about thirty-five nucleotides in length, where the length is governed by efficiency of inhibition, specificity, including absence of cross-reactivity, and the like. It has been found that short oligonucleotides, of from seven to  
10 eight bases in length, can be strong and selective inhibitors of gene expression (see Wagner *et al.* (1996) Nat. Biotech. 14, 840-844).

A specific region or regions of the endogenous sense strand mRNA sequence is chosen to be complemented by the antisense sequence. Selection of a specific sequence for the oligonucleotide may use an empirical method, where several candidate sequences are assayed for  
15 inhibition of expression of the target gene in an *in vitro* or animal model. A combination of sequences may also be used, where several regions of the mRNA sequence are selected for antisense complementation.

Antisense oligonucleotides may be chemically synthesized by methods known in the art (see Wagner *et al.* (1996) Nat. Biotech. 14, 840-844). Preferred oligonucleotides are chemically  
20 modified from the native phosphodiester structure, in order to increase their intracellular stability and binding affinity. A number of such modifications have been described in the literature, which alter the chemistry of the backbone, sugars or heterocyclic bases.

As an alternative to anti-sense inhibitors, catalytic nucleic acid compounds, *e.g.*, ribozymes, anti-sense conjugates, etc. may be used to inhibit gene expression. Ribozymes may  
25 be synthesized *in vitro* and administered to the patient, or may be encoded on an expression vector, from which the ribozyme is synthesized in the targeted cell (see, for example, WO 95/23225; Beigelman *et al.* (1995) Nucl. Acids Res. 23, 4434-4442). Examples of oligonucleotides with catalytic activity are described in WO 95/06764.

### 30 Methods to Identify Agents that Modulate Expression

Another embodiment of the present invention provides methods for identifying agents that modulate the expression of a nucleic acid encoding a protein of the invention such as a protein having the amino acid sequence of SEQ ID NO: 2. Such assays may utilize any available means of monitoring for changes in the expression level of the nucleic acids of the  
35 invention. As used herein, an agent is said to modulate the expression of a nucleic acid of the

invention if it is capable of up- or down-regulating expression of the nucleic acid in a cell.

In one assay format, cell lines that contain reporter gene fusions between the open reading frame defined by nucleotides 251-4,336 of SEQ ID NO: 1, or the 5' and/or 3' regulatory elements and any assayable fusion partner may be prepared. Numerous assayable fusion  
5 partners are known and readily available including the firefly luciferase gene and the gene encoding chloramphenicol acetyltransferase (Alam *et al.* (1990) Anal. Biochem. 188, 245-254). Cell lines containing the reporter gene fusions are then exposed to the agent to be tested under appropriate conditions and time. Differential expression of the reporter gene between samples exposed to the agent and control samples identifies agents that modulate the expression of a  
10 nucleic acid of the invention.

Additional assay formats may be used to monitor the ability of the agent to modulate the expression of a nucleic acid encoding a protein of the invention, such as the protein having SEQ ID NO: 2. For instance, mRNA expression may be monitored directly by hybridization to the  
15 nucleic acids of the invention. Cell lines are exposed to the agent to be tested under appropriate conditions and time and total RNA or mRNA is isolated by standard procedures such those disclosed in Sambrook *et al.* (1989) Molecular Cloning - A Laboratory Manual, Cold Spring Harbor Laboratory Press).

Probes to detect differences in RNA expression levels between cells exposed to the agent and control cells may be prepared from the nucleic acids of the invention. It is preferable,  
20 but not necessary, to design probes which hybridize only with target nucleic acids under conditions of high stringency. Only highly complementary nucleic acid hybrids form under conditions of high stringency. Accordingly, the stringency of the assay conditions determines the amount of complementation that should exist between two nucleic acid strands in order to form a hybrid. Stringency should be chosen to maximize the difference in stability between the  
25 probe:target hybrid and probe:non-target hybrids.

Probes may be designed from the nucleic acids of the invention through methods known in the art. For instance, the G+C content of the probe and the probe length can affect probe binding to its target sequence. Methods to optimize probe specificity are commonly available in  
30 Sambrook *et al.* (1989) Molecular Cloning - A Laboratory Manual, Cold Spring Harbor Laboratory Press or Ausubel *et al.* (1995) Current Protocols in Molecular Biology, Greene Publishing Co.

Hybridization conditions are modified using known methods, such as those described by Sambrook *et al.* and Ausubel *et al.* as required for each probe. Hybridization of total cellular RNA or RNA enriched for polyA RNA can be accomplished in any available format. For  
35 instance, total cellular RNA or RNA enriched for polyA RNA can be affixed to a solid support

and the solid support exposed to at least one probe comprising at least one, or part of one of the sequences of the invention under conditions in which the probe will specifically hybridize.

Alternatively, nucleic acid fragments comprising at least one, or part of one of the sequences of the invention can be affixed to a solid support, such as a silicon chip or a porous glass wafer.

- 5 The glass wafer can then be exposed to total cellular RNA or polyA RNA from a sample under conditions in which the affixed sequences will specifically hybridize. Such solid supports and hybridization methods are widely available, for example, those disclosed in WO 95/11755. By examining for the ability of a given probe to specifically hybridize to an RNA sample from an untreated cell population and from a cell population exposed to the agent, agents which up or  
10 down regulate the expression of a nucleic acid encoding the protein having the sequence of SEQ ID NO: 2 are identified.

Hybridization for qualitative and quantitative analysis of mRNA may also be carried out by using a RNase Protection Assay (*i.e.*, RPA, see Ma *et al.* (1996) Methods 10, 273-238).

- Briefly, an expression vehicle comprising cDNA encoding the gene product and a phage specific  
15 DNA dependent RNA polymerase promoter (*e.g.*, T7, T3 or SP6 RNA polymerase) is linearized at the 3' end of the cDNA molecule, downstream from the phage promoter, wherein such a linearized molecule is subsequently used as a template for synthesis of a labeled antisense transcript of the cDNA by *in vitro* transcription. The labeled transcript is then hybridized to a mixture of isolated RNA (*i.e.*, total or fractionated mRNA) by incubation at 45°C overnight in a  
20 buffer comprising 80% formamide, 40 mM Pipes (pH 6.4), 0.4 M NaCl and 1 mM EDTA. The resulting hybrids are then digested in a buffer comprising 40 µg/ml ribonuclease A and 2 µg/ml ribonuclease. After deactivation and extraction of extraneous proteins, the samples are loaded onto urea/polyacrylamide gels for analysis.

- In another assay format, cells or cell lines are first identified which express the gene  
25 products of the invention physiologically. Cell and/or cell lines so identified would be expected to comprise the necessary cellular machinery such that the fidelity of modulation of the transcriptional apparatus is maintained with regard to exogenous contact of agent with appropriate surface transduction mechanisms and/or the cytosolic cascades. Further, such cells or cell lines would be transduced or transfected with an expression vehicle (*e.g.*, a plasmid or  
30 viral vector) construct comprising an operable non-translated 5'-promoter containing end of the structural gene encoding the instant gene products fused to one or more antigenic fragments, which are peculiar to the instant gene products, wherein said fragments are under the transcriptional control of said promoter and are expressed as polypeptides whose molecular weight can be distinguished from the naturally occurring polypeptides or may further comprise  
35 an immunologically distinct tag or other detectable marker. Such a process is well known in the

art (see Sambrook *et al.* (1989) Molecular Cloning - A Laboratory Manual, Cold Spring Harbor Laboratory Press).

Cells or cell lines transduced or transfected as outlined above are then contacted with agents under appropriate conditions; for example, the agent in a pharmaceutically acceptable excipient is contacted with cells in an aqueous physiological buffer such as phosphate buffered saline (PBS) at physiological pH, Eagles balanced salt solution (BSS) at physiological pH, PBS or BSS comprising serum or conditioned media comprising PBS or BSS and/or serum incubated at 37°C. Said conditions may be modulated as deemed necessary by one of skill in the art. Subsequent to contacting the cells with the agent, said cells will be disrupted and the polypeptides of the lysate are fractionated such that a polypeptide fraction is pooled and contacted with an antibody to be further processed by immunological assay (*e.g.*, ELISA, immunoprecipitation or Western blot). The pool of proteins isolated from the "agent-contacted" sample will be compared with a control sample where only the excipient is contacted with the cells and an increase or decrease in the immunologically generated signal from the agent-contacted sample compared to the control will be used to distinguish the effectiveness of the agent.

#### Methods to Identify Agents that Modulate Activity

The present invention provides methods for identifying agents that modulate at least one activity of a protein of SEQ ID NO: 2. Such methods or assays may utilize any means of monitoring or detecting the desired activity.

In one format, the specific activity of a protein of the invention, normalized to a standard unit, between a cell population that has been exposed to the agent to be tested compared to an un-exposed control cell population may be assayed. Cell lines or populations are exposed to the agent to be tested under appropriate conditions and time. Cellular lysates may be prepared from the exposed cell line or population and a control, unexposed cell line or population. The cellular lysates are then analyzed with the probe.

Antibody probes can be prepared by immunizing suitable mammalian hosts utilizing appropriate immunization protocols using the proteins of the invention or antigen-containing fragments thereof. To enhance immunogenicity, these proteins or fragments can be conjugated to suitable carriers. Methods for preparing immunogenic conjugates with carriers such as BSA, KLH or other carrier proteins are well known in the art. In some circumstances, direct conjugation using, for example, carbodiimide reagents may be effective; in other instances linking reagents such as those supplied by Pierce Chemical Co. may be desirable to provide accessibility to the hapten. The hapten peptides can be extended at either the amino or carboxy

terminus with a cysteine residue or interspersed with cysteine residues, for example, to facilitate linking to a carrier. Administration of the immunogens is conducted generally by injection over a suitable time period and with use of suitable adjuvants, as is generally understood in the art. During the immunization schedule, titers of antibodies are taken to determine adequacy of antibody formation.

While the polyclonal antisera produced in this way may be satisfactory for some applications, for pharmaceutical compositions, use of monoclonal preparations is preferred. Immortalized cell lines which secrete the desired monoclonal antibodies may be prepared using standard methods, see *e.g.*, Kohler & Milstein (1992) *Biotechnology* 24, 524-526 or modifications which effect immortalization of lymphocytes or spleen cells, as is generally known. The immortalized cell lines secreting the desired antibodies can be screened by immunoassay in which the antigen is the peptide hapten, polypeptide or protein. When the appropriate immortalized cell culture secreting the desired antibody is identified, the cells can be cultured either *in vitro* or by production in ascites fluid.

The desired monoclonal antibodies may be recovered from the culture supernatant or from the ascites supernatant. Fragments of the monoclonal antibodies or the polyclonal antisera that contain the immunologically significant portion can be used as antagonists, as well as the intact antibodies. Use of immunologically reactive fragments, such as Fab or Fab' fragments, is often preferable, especially in a therapeutic context, as these fragments are generally less immunogenic than the whole immunoglobulin.

The antibodies or fragments may also be produced, using current technology, by recombinant means. Antibody regions that bind specifically to the desired regions of the protein can also be produced in the context of chimeras with multiple species origin.

Antibody regions that bind specifically to the desired regions of the protein can also be produced in the context of chimeras with multiple species origin, for instance, humanized antibodies. The antibody can therefore be a humanized antibody or human a antibody, as described in U.S. Patent 5,585,089 or Riechmann *et al.* (1988) *Nature* 332, 323-327.

Agents that are assayed in the above method can be randomly selected or rationally selected or designed. As used herein, an agent is said to be randomly selected when the agent is chosen randomly without considering the specific sequences involved in the association of the a protein of the invention alone or with its associated substrates, binding partners, etc. An example of randomly selected agents is the use a chemical library or a peptide combinatorial library, or a growth broth of an organism.

As used herein, an agent is said to be rationally selected or designed when the agent is chosen on a non-random basis which takes into account the sequence of the target site or its



conformation in connection with the agent's action. Agents can be rationally selected or rationally designed by utilizing the peptide sequences that make up these sites. For example, a rationally selected peptide agent can be a peptide whose amino acid sequence is identical to or a derivative of any functional consensus site.

5       The agents of the present invention can be, as examples, peptides, peptide mimetics, antibodies, antibody fragments, small molecules, vitamin derivatives, as well as carbohydrates. Peptide agents of the invention can be prepared using standard solid phase (or solution phase) peptide synthesis methods, as is known in the art. In addition, the DNA encoding these peptides may be synthesized using commercially available oligonucleotide synthesis instrumentation and  
10       produced recombinantly using standard recombinant production systems. The production using solid phase peptide synthesis is necessitated if non-gene-encoded amino acids are to be included.

Another class of agents of the present invention are antibodies or fragments thereof that bind to a protein of SEQ ID NO: 2. Antibody agents can be obtained by immunization of suitable mammalian subjects with peptides, containing as antigenic regions, those portions of the  
15       protein intended to be targeted by the antibodies.

In yet another class of agents, the present invention includes peptide mimetics that mimic the three-dimensional structure of the protein of SEQ ID NO: 2. Such peptide mimetics may have significant advantages over naturally occurring peptides, including, for example: more economical production, greater chemical stability, enhanced pharmacological properties (half-  
20       life, absorption, potency, efficacy, etc.), altered specificity (e.g., a broad-spectrum of biological activities), reduced antigenicity and others.

In one form, mimetics are peptide-containing molecules that mimic elements of protein secondary structure. The underlying rationale behind the use of peptide mimetics is that the peptide backbone of proteins exists chiefly to orient amino acid side chains in such a way as to  
25       facilitate molecular interactions, such as those of antibody and antigen. A peptide mimetic is expected to permit molecular interactions similar to the natural molecule.

In another form, peptide analogs are commonly used in the pharmaceutical industry as non-peptide drugs with properties analogous to those of the template peptide. These types of non-peptide compounds are also referred to as peptide mimetics or peptidomimetics (Fauchere  
30       (1986) Adv. Drug Res. 15, 29-69; Veber & Freidinger (1985) Trends Neurosci. 8, 392-396; Evans *et al.* (1987) J. Med. Chem. 30, 1229-1239 which are incorporated herein by reference) and are usually developed with the aid of computerized molecular modeling.

Peptide mimetics that are structurally similar to therapeutically useful peptides may be used to produce an equivalent therapeutic or prophylactic effect. Generally, peptide mimetics  
35       are structurally similar to a paradigm polypeptide (*i.e.*, a polypeptide that has a biochemical

property or pharmacological activity), but have one or more peptide linkages optionally replaced by a linkage by methods known in the art.

Labeling of peptide mimetics usually involves covalent attachment of one or more labels, directly or through a spacer (e.g., an amide group), to non-interfering positions on the peptide mimetic that are predicted by quantitative structure-activity data and molecular modeling. Such non-interfering positions generally are positions that do not form direct contacts with the macromolecules to which the peptide mimetic binds to produce the therapeutic effect. Derivatization (e.g., labeling) of peptide mimetics should not substantially interfere with the desired biological or pharmacological activity of the peptide mimetic.

The use of peptide mimetics can be enhanced through the use of combinatorial chemistry to create drug libraries. The design of peptide mimetics can be aided by identifying amino acid mutations that increase or decrease binding of the protein to its binding partners. Approaches that can be used include the yeast two hybrid method (see Chien *et al.* (1991) Proc. Natl. Acad. Sci. USA 88, 9578-9582) and using the phage display method. The two hybrid method detects protein-protein interactions in yeast (Fields *et al.* (1989) Nature 340, 245-246). The phage display method detects the interaction between an immobilized protein and a protein that is expressed on the surface of phages such as lambda and M13 (Amberg *et al.* (1993) Strategies 6, 2-4; Hogrefe *et al.* (1993) Gene 128, 119-126). These methods allow positive and negative selection for protein-protein interactions and the identification of the sequences that determine these interactions.

#### Diagnostic Methods and Agents

As described above, expression of the proteins and nucleic acids of the invention may be used as a diagnostic marker for the prediction or identification of the differentiation state of a sample comprising precursor stem cells. In some embodiments, the tissue sample is a bone biopsy. For instance, a tissue sample may be assayed by any of the methods described above, and expression levels of the proteins or nucleic acids of the invention may be compared to the expression levels found in undifferentiated precursor stem cells and/or precursor stem cells induced to differentiate into osteoblasts and/or precursor stem cells induced to differentiate into a cell type other than an osteoblast. Such methods may be used to diagnose or identify conditions characterized by abnormal bone deposition, reabsorption and/or abnormal rates of osteoblast differentiation.

Those skilled in the art will appreciate that a wide variety of conditions are associated with abnormal bone deposition or loss. Such conditions include, but are not limited to, osteoporosis, osteopenia, osteodystrophy, and various other osteopathic conditions. The

methods of the present invention will be particularly useful in diagnosing or monitoring the treatment of conditions such as postmenopausal osteoporosis (PMO), glucocorticoid-induced osteoporosis (GIO), and male osteoporosis. Agents which modulate expression of the nucleic acids or proteins of the invention will be useful in treatment of these conditions.

5 In some preferred embodiments, the present invention may be used to diagnose and/or monitor the treatment of drug-induced abnormalities in bone formation or loss. For example, at present a combination of cyclosporine with prednisone is given to patients who have received an organ transplant in order to suppress tissue rejection. The combination causes rapid bone loss in a manner different than that observed with prednisone alone (such as elevated level of serum  
10 osteocalcin and vitamin D in patients treated with cyclosporine but not in patients treated with prednisone). Other drugs are also known to effect bone formation or loss. The anticonvulsant drugs diphenylhydantoin, phenobarbital and carbamazepine, and combination of these drugs, cause alterations in calcium metabolism. A decrease in bone density is observed in patients taking anticonvulsant drugs. Although heparin is an effective therapy for thromboembolic  
15 disorders, increased incidences of osteoporotic fractures have been reported in patients with heparin therapy hence the present invention will be useful to monitor patients undergoing heparin treatment.

Other embodiments of the present invention allow the diagnosis and/or monitoring of the treatment of other conditions that involve altered bone metabolism. For example, idiopathic  
20 juvenile osteoporosis (IJO) is a generalized decrease in mineralized bone in the absence of rickets or excessive bone resorption and typically occurs in children before the onset of puberty. In addition, thyroid diseases have been linked to bone loss. A decrease in bone mass has been shown in patients with thyrotoxicosis causing these individuals to be at increased risk of having fractures. These individuals also sustain fractures at an earlier age than individuals who have  
25 never been thyrotoxic.

Another situation in which the present invention will be useful is the diagnosis and/or monitoring of the treatment of skeletal disease linked to breast cancer. Breast cancer frequently metastasizes to the skeleton and about 70% of patients with advanced cancer develop symptomatic skeletal disease. Moreover, the anti-cancer treatments presently in use have been  
30 shown to lead to early menopause and bone loss when given to premenopausal women.

The present invention will be useful in diagnosing and/or monitoring the treatment of chronic anemia associated with abnormal bone formation or loss. Homozygous beta-thalassemia is usually described as an example of chronic anemia predisposing to osteoporosis. Patients with thalassemia have expansion of bone marrow space with thinning of the adjacent trabeculae.

35 Other conditions in which the present invention will find application are: Fanconi

syndrome where osteomalacia is a common feature; fibrous dysplasia, McCune-Albright syndrome refers to patients with fibrous dysplasia with a sporadic, developmental disorder characterized by a unifocal or multifocal expanding fibrous lesion of bone-forming mesenchyme that often results in pain, fracture or deformity; osteogenesis imperfecta (OI, also called brittle

5 bone disease) is associated with recurrent fractures and skeletal deformity, various skeletal dysplasias *i.e.*, osteochondroplasia which is characterized by abnormal development of cartilage and/or bone and other diseases such as achondroplasia, mucopolysaccharidoses, dysostosis and ischemic bone diseases.

The present invention will be particularly useful by providing a marker that may be used

10 as a marker of bone turnover to determine osteoporosis. The present invention may also be used *in vitro* in assays or treatments as a marker of osteoblast differentiation and proliferation.

#### Modulation of Gene Expression

As provided in the Examples, the proteins and nucleic acids of the invention are

15 expressed on osteoblasts derived from mesenchymal stem cells. Agents that modulate or up- or down-regulate the expression of the protein or agents such as agonists or antagonists of at least one activity of the proteins of the invention may be used to modulate biological and pathologic processes associated with the protein's function and activity. The invention is particularly useful in the treatment of human subjects.

Pathological processes refer to a category of biological processes that produce a deleterious effect. For example, expression of the proteins of the invention is associated with differentiation of stem cells into osteoblasts under normal conditions but in a disease state, the necessary level of expression of the proteins may not be present. Such diseases include, but are not limited to, diseases caused by an abnormal rate of osteoblast formation and subsequent

25 activity. Decreased osteoblast activity can lead to a decrease in bone deposition with a concurrent increased osteoclast activity resulting in abnormal increase in bone resorption ultimately leading to decreased bone density.

As discussed above, those skilled in the art will appreciate that a wide variety of conditions are associated with an abnormal rate of osteoblast formation leading to abnormal

30 bone deposition or loss. Such conditions include, but are not limited to, osteoporosis, osteopenia, osteodystrophy, and various other osteopathic conditions. The methods of the present invention will be particularly useful in the treatment of conditions such as postmenopausal osteoporosis (PMO), glucocorticoid-induced osteoporosis (GIO), and male osteoporosis. Agents which modulate expression of the proteins of this invention will be useful

35 in treatment of these conditions.

Osteoporosis is an example of one such disease characterized by abnormal bone density.

As used herein, an agent is said to modulate a pathological process when the agent reduces the degree or severity of the process. For instance, a bone density disorder may be prevented or disease progression modulated by the administration of agents which reduce, promote or modulate in some way the expression or at least one activity of the proteins and nucleic acids of the invention, such as the protein having the amino acid sequence of SEQ ID NO: 2. For osteoporosis, the therapeutic strategy comprises a treatment with the agent until normal bone mass compared to appropriate control groups is restored. Bone mass can be assessed by determining bone mineral density. Then the treatment can be switched to established regimens for the prevention of bone loss to avoid potential side effects of overshooting bone formation.

Other embodiments of the present invention allow for the treatment of other conditions that involve altered bone metabolism associated with osteoblast activity, *e.g.*, idiopathic juvenile osteoporosis (IJO). In addition, thyroid diseases have been linked to bone loss. A decrease in bone mass has been shown in patients with thyrotoxicosis causing these individuals to be at increased risk of having fractures. These individuals also sustain fractures at an earlier age than individuals who have never been thyrotoxic.

The present invention will be useful in the treatment of abnormal bone formation or loss associated with chronic anemia. Homozygous beta-thalassemia is usually described as an example of chronic anemia predisposing to osteoporosis. Patients with thalassemia have expansion of bone marrow space with thinning of the adjacent trabeculae.

Other conditions in which the present invention will find therapeutic application are: Fanconi syndrome where osteomalacia is a common feature; fibrous dysplasia, McCune-Albright syndrome refers to patients with fibrous dysplasia with a sporadic, developmental disorder characterized by a unifocal or multifocal expanding fibrous lesion of bone-forming mesenchyme that often results in pain, fracture or deformity; osteogenesis imperfecta (OI, also called brittle bone disease) is associated with recurrent fractures and skeletal deformity, various skeletal dysplasias *i.e.*, osteochondroplasia which is characterized by abnormal development of cartilage and/or bone and other diseases such as achondroplasia, mucopolysaccharidoses, dysostosis and ischemic bone diseases.

In one example, administration of soluble form of the protein of the invention can be used to treat a bone density disorder associated with the proteins' expression. Soluble receptors have been used to bind cytokines or other ligands to regulate their function (Thomson (1998) Cytokine Handbook, Academic Press).

The agents of the present invention can be provided alone, or in combination, or in sequential combination with other agents that modulate a particular pathological process. As

used herein, two agents are said to be administered in combination when the two agents are administered simultaneously or are administered independently in a fashion such that the agents will act at the same time. For example, the agents of the invention can be used in combination with estrogen replacement therapy in postmenopausal osteoporosis.

5       The agents of the present invention can be administered via parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, or buccal routes. For example, an agent may be administered locally to a site of injury via microinfusion. Alternatively, or concurrently, administration may be by the oral route. The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of  
10      treatment, and the nature of the effect desired.

      The present invention further provides compositions containing one or more agents that modulate expression or at least one activity of the proteins of the invention. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art. Typical dosages comprise 1 pg/kg to 100 mg/kg body weight. The preferred  
15      dosages for systemic administration comprise 100 ng/kg to 100 mg/kg body weight. The preferred dosages for direct administration to a site via microinfusion comprise 1 ng/kg to 1 mg/kg body weight.

      In addition to the pharmacologically active agent, the compositions of the present invention may contain suitable pharmaceutically acceptable carriers comprising excipients and  
20      auxiliaries that facilitate processing of the active compounds into preparations which can be used pharmaceutically for delivery to the site of action. Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include  
25      fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol and dextran. Optionally, the suspension may also contain stabilizers. Liposomes can also be used to encapsulate the agent for delivery into the cell.

30      The pharmaceutical formulation for systemic administration according to the invention may be formulated for enteral, parenteral or topical administration. Indeed, all three types of formulations may be used simultaneously to achieve systemic administration of the active ingredient. Suitable formulations for oral administration include hard or soft gelatin capsules, pills, tablets, including coated tablets, elixirs, suspensions, syrups or inhalations and controlled  
35      release forms thereof.

In practicing the methods of this invention, the agents of this invention may be used alone or in combination, or in combination with other therapeutic or diagnostic agents. In certain preferred embodiments, the compounds of this invention may be co-administered along with other compounds typically prescribed for these conditions according to generally accepted medical practice, such as anti-inflammatory agents, anticoagulants, antithrombotics, including platelet aggregation inhibitors, tissue plasminogen activators, urokinase, prourokinase, streptokinase, aspirin and heparin. The compounds of this invention can be utilized *in vivo*, ordinarily in mammals, such as humans, sheep, horses, cattle, pigs, dogs, cats, rats and mice, or *in vitro*.

### Prognostic Uses

As described above, the nucleic acids and proteins of the invention and their expression may also be used as markers for the monitoring of disease progression, such as osteoporosis. For instance, a tissue sample may be assayed by any of the methods described above, and the expression levels for the protein may be compared to the expression levels found in undifferentiated precursor stem cells and/or precursor stem cells induced to differentiate into osteoblasts and/or precursor stem cells induced to differentiate into a cell type other than an osteoblast and/or osteoblasts.

Expression or activity the proteins and nucleic acids of the invention, such as the protein having the amino acid sequence of SEQ ID NO: 2, may also be used to track or predict the progress or efficacy of a treatment regime in a patient. For instance, a patient's progress or response to a given drug may be monitored by measuring gene expression of the proteins of the invention in a tissue or cell sample after treatment or administration of the drug. The expression of the protein in the post-treatment sample may then be compared to gene expression from undifferentiated precursor stem cells and/or precursor stem cells induced to differentiate into osteoblasts and/or precursor stem cells induced to differentiate into a cell type other than an osteoblast and/or osteoblasts and/or from tissue or cells from the same patient before treatment.

### Transgenic Animals

Transgenic animals containing mutant, knock-out or modified genes corresponding to the cDNA sequence of SEQ ID NO: 1, or the open reading frame encoding the polypeptide sequence of SEQ ID NO: 2 or fragments thereof having a contiguous sequence of at least about one-thousand and fifteen amino acid residues, are also included in the invention. Transgenic animals are genetically modified animals into which recombinant, exogenous or cloned genetic material has been experimentally transferred. Such genetic material is often referred to as a

transgene. The nucleic acid sequence of the transgene, in this case a form of SEQ ID NO: 1 may be integrated either at a locus of a genome where that particular nucleic acid sequence is not otherwise normally found or at the normal locus for the transgene. The transgene may consist of nucleic acid sequences derived from the genome of the same species or of a different species than the species of the target animal.

The term "germ cell line transgenic animal" refers to a transgenic animal in which the genetic alteration or genetic information was introduced into a germ line cell, thereby conferring the ability of the transgenic animal to transfer the genetic information to offspring. If such offspring in fact possess some or all of that alteration or genetic information, then they too are transgenic animals.

The alteration or genetic information may be foreign to the species of animal to which the recipient belongs, foreign only to the particular individual recipient, or may be genetic information already possessed by the recipient. In the last case, the altered or introduced gene may be expressed differently than the native gene.

Transgenic animals can be produced by a variety of different methods including transfection, electroporation, microinjection, gene targeting in embryonic stem cells and recombinant viral and retroviral infection (see, e.g., U.S. Patents 4,736,866 & 5,602,307; Mullins *et al.* (1993) Hypertension 22, 630-633; Brenin *et al.* (1997) Surg. Oncol. 6, 99-110; Tuan (1997) Recombinant Gene Expression Protocols, Methods in Molecular Biology, Humana Press).

A number of recombinant or transgenic mice have been produced, including those which express an activated oncogene sequence (U.S. Patent 4,736,866); express simian SV40 T-antigen (U.S. Patent 5,728,915); lack the expression of interferon regulatory factor 1 (IRF-1) (U.S. Patent 5,731,490); exhibit dopaminergic dysfunction (U.S. Patent 5,723,719); express at least one human gene which participates in blood pressure control (U.S. Patent 5,731,489); display greater similarity to the conditions existing in naturally occurring Alzheimer's disease (U.S. Patent 5,720,936); have a reduced capacity to mediate cellular adhesion (U.S. Patent 5,602,307); possess a bovine growth hormone gene (Clutter *et al.* (1996) Genetics 143, 1753-1760); or are capable of generating a fully human antibody response (McCarthy (1997) Lancet 349, 405-406).

While mice and rats remain the animals of choice for most transgenic experimentation, in some instances it is preferable or even necessary to use alternative animal species. Transgenic procedures have been successfully utilized in a variety of non-murine animals, including sheep, goats, pigs, dogs, cats, monkeys, chimpanzees, hamsters, rabbits, cows and guinea pigs (see, e.g., Kim *et al.* (1997) Mol. Reprod. Dev. 46, 515-526; Houdebine (1995) Reprod. Nutr. Dev.



35, 609-617; Petters (1994) *Reprod. Fertil. Dev.* 6, 643-645; Schnieke *et al.* (1997) *Science* 278, 2130-2133; and Amoah (1997) *J. Animal Science* 75, 578-585).

The method of introduction of nucleic acid fragments into recombination competent mammalian cells can be by any method that favors co-transformation of multiple nucleic acid molecules. Detailed procedures for producing transgenic animals are readily available to one skilled in the art, including the disclosures in U.S. Patents 5,489,743 & 5,602,307.

Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the present invention and practice the claimed methods. The following working examples therefore, specifically point out the preferred embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.

## EXAMPLES

### Example 1

#### Cloning of Full Length Human Gene

The full length cDNA having SEQ ID NO: 1 was obtained by the solution hybridization method. Briefly, a gene-specific oligonucleotide was designed based on the sequence of an EST fragment identified by READS analysis (Prashar *et al.* (1996) 93, 659-663).

The oligonucleotide was labeled with biotin and used to hybridize with 5 µg of single strand plasmid DNA (cDNA recombinants) from a human resting mast cell library following the procedures from the Gene Trapper kit (Life Technologies). The hybridized cDNA was separated by streptavidin-conjugated beads and eluted by Tris-EDTA buffer. The eluted cDNA was converted to double strand plasmid DNA and used to transform *E. coli* cells (DH5α). Clones were screened by PCR using gene specific primers designed from the EST sequence to identify positive clones. After positive selection, the cDNA clone was subjected to DNA sequence.

The nucleotide sequences of the full-length human cDNA corresponding to the differentially regulated mRNA detected above is set forth in SEQ ID NO: 1. The cDNA comprises 7,084 base pairs, with an open reading frame at nucleotides 251-4,336 encoding a protein of 1,361 amino acids (nucleotides 251-4,335 without the TAA stop codon). The amino acid sequence corresponding to the encoded protein is set forth in SEQ ID NO: 2. Figure 6 displays the results of a hydrophobicity analysis of the polypeptide of SEQ ID NO: 2 using the methods of Kyte & Doolittle (1982) *J. Mol. Biol.* 157, 105-132.

### Example 2

Down-regulation of Expression in hFSC

Human Fetal Stromal Cells (hFSC) were isolated from the bone marrow of a twenty-week human embryo. hFSCs are derived from a primary culture and represent a heterogeneous population of osteoprogenitor cells. hFSCs exhibit a high replicative capacity, with a doubling time of approximately twenty hours. hFSCs retain a spindle-shaped morphology and have a uniform attachment throughout subcultivation. hFSCs can be sub-cultured up to twelve passages while retaining both proliferative and osteogenic capability.

hFSCs used for READS analysis or Q-PCR were cultured in Dulbecco's Modified Eagle Medium (DMEM)-high glucose or DMEM-low glucose plus 10% fetal bovine serum, respectively, at 37°C in a humidified atmosphere containing 95% air and 5% carbon dioxide in the absence and presence of the indicated treatment. RNA was extracted from the cells at thirty minutes, three hours, six hours, twelve hours, twenty-four hours, forty-eight hours, three days, six days, twelve days and twenty-four days. When indicated, cells were contacted with either bone morphogenic protein-2 (BMP-2) at 300 ng/ml or transforming growth factor beta (TGF-β) at 1 ng/ml. Cells were incubated for the period of time indicated and harvested.

Total cellular RNA was prepared from the human fetal stromal cells described above. Synthesis of cDNA was performed as previously described in WO 97/05286 and in Prashar *et al.* (1996) Proc. Natl. Acad. Sci. USA 93, 659-663. Briefly, cDNA was synthesized according to the protocol described in the Gibco-BRL kit for cDNA synthesis. The reaction mixture for first-strand synthesis included 0.006 mg of total RNA, and 200 ng of a mixture of one-base anchored oligo(dT) primers with all three possible anchored bases (acgtaacgactcactatagggcgaattgggtcgact<sub>17</sub>n1 wherein n1 = a, c or g) (SEQ ID NO: 3) along with other components for first-strand synthesis reaction except reverse transcriptase. This mixture was incubated at 65°C for five minutes, chilled on ice and the process repeated.

Alternatively, the reaction mixture may include 0.010 mg of total RNA, and 2 pmol of one of the two base anchored oligo(dT) primers annealed such as RP5 (ctctcaaggatcttaccgctt<sub>18</sub>at) (SEQ ID NO: 4), RP6 (taataccgcgccacatagcat<sub>18</sub>cg) (SEQ ID NO: 5) or RP92 (cagggtagacgacgctacgct<sub>18</sub>ga) (SEQ ID NO: 6) along with other components for first-strand synthesis reaction except reverse transcriptase. This mixture was then layered with mineral oil and incubated at 65°C for seven minutes followed by 50°C for another seven minutes. At this stage, 0.002 ml of Superscript<sup>®</sup> reverse transcriptase (Gibco-BRL) (200 units per microliter) was added quickly and mixed, and the reaction continued for one hour at 45-50°C. Second-strand synthesis was performed at 16°C for two hours. At the end of the reaction, the cDNA were precipitated with ethanol and the yield of cDNA was calculated. In these experiments, 200 ng of cDNA was obtained from 0.010 mg of total RNA. The adapter oligonucleotide sequences were

A1 (tagcgtccggcgacgcagcggccag) (SEQ ID NO: 7) and A2 (gacctggccgctcggctgtctcggcgc) (SEQ ID NO: 8).

One microgram of oligonucleotide A2 was first phosphorylated at the 5' end using T4 polynucleotide kinase (PNK). After phosphorylation, PNK was heated denatured and 0.001 mg of the oligonucleotide A1 was added along with 10× annealing buffer (1 M NaCl/100 mM Tris-HCl (pH 8.0)/10 mM EDTA (pH 8.0)) in a final volume of 0.020 ml. This mixture was then heated at 65°C for ten minutes followed by slow cooling to room temperature for thirty minutes, resulting in formation of the Y adapter at a final concentration of 100 ng per microliter. About 20 ng of the cDNA was digested with four units of BglII in a final volume of 0.01 ml for thirty minutes at 37°C. Two microliters (4 ng of digested cDNA) of this reaction mixture was then used for ligation to 100 ng (fifty-fold) of the Y-shaped adapter in a final volume of 0.005 ml for sixteen hours at 15°C. After ligation, the reaction mixture was diluted with water to a final volume of 0.080 ml (adapter ligated cDNA concentration, 0.05 ng/ml) and heated at 65°C for ten minutes to denature T4 DNA ligase and 0.002 ml aliquots (with 100 pg of cDNA) were used for PCR.

The following sets of primers were used for PCR amplification of the adapter ligated 3'-end cDNA: tgaagccgagacgtcggcg(t)<sub>18</sub> n1, n2 (SEQ ID NO: 9) (wherein n1, n2 = aa, ac, ag, at, ca, cc, cg, ct, ga, gc, gg and gt) as the 3' primer with A1 as the 5' primer or alternatively P5, RP6 or RP92 used as 3' primers with primer A1.1 serving as the 5' primer. To detect the PCR products on the display gel, 24 pmol of oligonucleotide A1 or A11 was 5'-end labeled using 0.015 ml of gamma-[<sup>32</sup>P]ATP (Amersham; 3000 Ci/mmol) and PNK in a final volume of 0.020 ml for thirty minutes at 37°C. After heat denaturing PNK at 65°C for twenty minutes, the labeled oligonucleotide was diluted to a final concentration of 0.002 mM in 0.080 ml with unlabeled oligonucleotide A11. The PCR mixture (0.020 ml) consisted of 0.002 ml (100 pg) of the template, 0.002 ml of 10× PCR buffer (100 mM Tris-HCl (pH 8.3)/500 mM KCl), 0.002 ml of 15 mM magnesium chloride to yield 1.5 mM final magnesium concentration optimum in the reaction mixture, 0.20 mM dNTPs, 200 nM each 5' and 3' PCR primers, and one unit of Amplitaq Gold® DNA polymerase.

Primers and dNTPs were added after preheating the reaction mixture containing the rest of the components at 85°C. This "hot start" PCR was done to avoid amplification artifacts arising out of arbitrary annealing of PCR primers at lower temperature during transition from room temperature to 94°C in the first PCR cycle. PCR consisted of five cycles of 94°C for thirty seconds, 55°C for two minutes and 72°C for sixty seconds followed by twenty-five cycles of 94°C for thirty seconds, 60°C for two minutes, and 72°C for sixty seconds. A higher number of cycles resulted in smeary gel patterns. PCR products (0.0025 ml) were analyzed on 6%

polyacrylamide sequencing gel. For double or multiple digestion following adapter ligation, 0.0132 ml of the ligated cDNA sample was digested with a secondary restriction enzymes in a final volume of 0.020 ml. From this solution, 0.003 ml was used as template for PCR. This template volume of carried 100 pg of the cDNA and 10 mM magnesium chloride (from the 10× enzyme buffer), which diluted to the optimum of 1.5 mM in the final PCR volume of 0.020 ml. Since magnesium comes from the restriction enzyme buffer, it was not included in the reaction mixture when amplifying secondarily cut cDNA.

Individual cDNA fragments corresponding to nucleic acid molecules of SEQ ID NO: 1 were separated by denaturing polyacrylamide gel electrophoresis and visualized by autoradiography. Bands identified as having different expression levels in treated versus untreated human fetal stromal cells were extracted from the display gels as described by Liang *et al.* (1995) *Curr. Opin. Immunol.* 7, 274-280), reamplified using the 5' and 3' primers, and subcloned into PCR-Script with high efficiency using the PCR-Script® cloning kit (Stratagene). Plasmids were sequenced by cycle sequencing on an ABI automated sequencer. Alternatively, bands were extracted (cored) from the display gels, PCR amplified and sequenced directly without subcloning.

Figures 1A and B present a graphic depiction of the expression level of the target mRNA of SEQ ID NO: 1 whose expression pattern was found to be dependent upon the activation state of the precursor stem cells. These figures represent the data obtained from READS gel analysis of the mRNA expression data from hFSC. READS analysis (as described above) was performed on total RNA samples isolated from hFSC that were treated with TGF-β (1 ng/ml of culture media) for twenty-four days in Figure 1A and forty-eight hours in Figure 1B. Time points for Figure 1A were selected at one, three, six, twelve and twenty-four days post-initial treatment. Time points for Figure 1B were selected at three, six, twelve, twenty-four and forty-eight hours.

Figures 2A and B present a graphic depiction of the expression level of the target mRNA of SEQ ID NO: 1. READS analysis (as described above) was performed on total RNA samples isolated from hFSC that were treated with BMP-2 (300 ng/ml of culture media) for twenty-four days in Figure 2A and forty-eight hours in Figure 2B. Time points for Figure 2A were selected at one, three, six, twelve and twenty-four days post-initial treatment. Time points for Figure 2B were selected at three, six, twelve, twenty-four and forty-eight hours.

Figures 3A, 3B and 3C provides a graphical representation of the expression level of the target mRNA of SEQ ID NO: 1 in human mesenchymal stem cells as assayed using READS gel analysis in response to treatment with osteogenic and adipogenic agents. In Figure 3A, cells were cultured in a medium supplemented with 10% fetal calf serum with or without

dexamethasone for time period ranging from zero to seven days). In Figure 3B, cells were cultured in the same manner with or without BMP-2 for the same time period. In Figure 3C, cells were cultured in a medium containing 10% rabbit serum with or without addition of dexamethasone for the same time period.

Control cells received media only with no added osteogenic agent or adipogenic agent. Subsequent to READS gel analysis, the images of each gel were converted into electronic format and the intensities of each band of interest were calculated relative to the background autoradiographic intensity of each gel image. The corrected values are termed adjusted intensity values, which were plotted on the y-axis versus the time course of the experiment.

### Example 3

#### Quantitative RT-PCR analysis of Expression in hFSC and hMSC

Both human fetal stromal cells (hFSC) and hMSC were used for this study as in the READS experiments. Briefly, PCR primers and TaqMan probes were designed using the DNA sequences provided by sequence analysis of the nucleic acid molecule of SEQ ID NO: 1. Experimental conditions were as follows: hFSC were cultured *in vitro* and were left untreated for up to twenty-four days, or were treated with the osteogenic agents TGF- $\beta$  (1 ng/ml of culture media) or BMP-2 (300 ng/ml) for the same time period.

Cells in each of the treatment groups were harvested at various time points after addition of TGF- $\beta$  or BMP-2. Total RNA was isolated from the cells using Trizol<sup>®</sup> and the RNA was quantitated using a spectrophotometer set at 260 nm. Ten ng of total RNA was assayed in duplicate using the TaqMan<sup>®</sup> assay (Perkin-Elmer) in biplex format where each target gene in each RNA sample was assayed versus a reference mRNA which was shown previously to be constitutively expressed and not regulated by any of the osteogenic treatments. The Ct values of the target and reference gene were analyzed and the delta Ct values were calculated for each RNA sample. Fold change (expressed as relative expression) was plotted versus the time course of the experiment. Expression was relative to the delta Ct value (Target Ct minus Reference Ct) for t = 0 which was set to a value of 1.0.

Figure 4 shows expression levels of the target mRNA of SEQ ID NO: 1 in human fetal stromal cells (A and B) and in human mesenchymal stromal cells (C) as assayed by quantitative RT-PCR. In Figure 4A, cells were cultured using non-mineralization conditions in the absence or presence of either 1 ng/ml TGF- $\beta$ 1 or 300 ng/ml of BMP-2 (closed triangles) for time periods up to six days. In Figure 4B, cells were cultured using mineralization conditions in the absence of the same agents of Figure 4A for time periods up to twenty-one days. In Figure 4C, mesenchymal stromal cells were cultured in the presence of ascorbic acid and  $\beta$ -

glycerophosphate in the absence and presence of either TGF- $\beta$ 1, BMP-2 or dexamethasone for time periods up to sixteen days.

#### Example 4

##### 5 Expression in human tissues

The tissue distribution of mRNA encoding the 76032 gene (SEQ ID NO: 1) was analyzed by quantitative PCR expression analysis of RNA isolated from various tissues. RNA was isolated from human kidney, spinal cord, adrenal gland, adipose tissue, heart, skeletal tissue, colon, pancreas, liver, prostate, thyroid, brain, stomach, small intestine, bone marrow, thymus, spleen, lung, uterus, mammary gland and trachea using standard procedures. PCR expression analysis was also performed using primers derived from the 76032 sequence using AmpliTaq<sup>®</sup> PCR amplification kits (Perkin Elmer). The presence of variable levels of mRNA encoding SEQ ID NO: 2 was detected in several tissues other than hFSC and hMSC (Figure 5). mRNA expression was most abundant in the spinal cord, adipose tissue and prostate. Detectable lower levels were observed in all other tissues tested.

Figure 5 shows expression levels, depicted as Ct values, of the target mRNA of SEQ ID NO: 1 in various human tissues as assayed using TaqMan quantitative RT-PCR methods (described above). The Ct values are displayed on the y axis whereas the tissue panel utilized in the assay is provided on the x axis. Expression levels of the target mRNA in resting human fetal stromal cells (HFSC control) and human mesenchymal stem cells (MSC control) is also provided

#### Example 5

##### Northern Blot Analysis

Figures 7 and 8 show a Northern blot in which the expression level of SEQ ID NO: 1 was measured in several normal human tissues including brain, heart, skeletal muscle, colon, thymus, spleen, kidney, liver, small intestine, placenta, lung and in leukocytes (ClonTech human mRNA blot-H12) as well as induced stem cells. RNA markers are present on the left side of the blot. Briefly, a cDNA clone corresponding to SEQ ID NO: 1, was radiolabeled using random primer labeling technology and the resulting probe was hybridized onto the blot during a sixteen hour incubation at 42°C in a 50% formamide hybridization solution. After the hybridization, the blot was washed in 0.1× SSC, 0.1% SDS at 42°C for up to two hours. After washing, the blot was exposed to film for a period of twenty-four hours at -80°C prior to development to obtain the figure shown. Figure 8 shows a Northern blot in which the expression level of SEQ ID NO: 1 was measured in human tissues as well as in human fetal stromal cells (FSC) and

mesenchymal stem cells (MSC) either resting or treated with osteogenic agents. A radiolabeled probe corresponding to SEQ ID NO: 1 was constructed as described above and was hybridized onto the blot in Church-Gilbert solution for sixteen hours at 65°C. After hybridization, the blot was washed in 0.5× SSC, 0.1% SDS at room temperature for two hours before exposure to film.

5 The resulting autorad is shown in the Figure 8.

#### Example 6

##### Drug Screening Assays

Candidate agents and compounds will be screened for their ability to modulate the expression levels and/or activities of the gene comprising SEQ ID NO: 1 and identified as being involved in the differentiation of precursor stem cells into osteoblasts by any technique known to those skilled in the art including those assays described above. In some preferred embodiments, the assay of gene expression level may be conducted using real time PCR. Real time PCR detection may be accomplished by the use of the ABI Prism 7700 Sequence Detection System.

10 The 7700 measures the fluorescence intensity of the sample each cycle and is able to detect the presence of specific amplicons within the PCR reaction. Each sample is assayed for the level of 76032 gene expression identified as being involved in the differentiation of precursor cells into osteoblasts.

The expression level of a control gene, for example GAPDH, may be used to normalize the expression levels. Suitable primers for the candidate genes may be selected using techniques well known to those skilled in the art. These primers may be used in conjunction with SYBR green (Molecular Probes), a nonspecific double stranded DNA dye, to measure the expression level mRNA corresponding to the 76032 gene, which will typically be normalized to the GAPDH level in each sample.

25 Normalized expression levels from cells exposed to the agent are then compared to the normalized expression levels in control cells. Agents that modulate the expression of the protein of this invention may be further tested as drug candidates in appropriate *in vitro* and *in vivo* models.

#### 30 Example 7

##### Inhibition of 76032 gene expression increases osteoblast differentiation

Human mesenchymal stromal cells (hMSCs) were used for this study in addition to short interfering RNA (siRNA) designed to inhibit the expression of mRNA transcripts for the 76032 gene. siRNA effects were controlled using a control siRNA duplex containing an

35 identical combination of bases which does not affect 76032 expression. Each well of a 48 well

plate was incubated with 0.1nM siRNA 0.005 mg Lipofectamine® 2000 (Invitrogen) for fifteen minutes. The total volume of this solution was then made up to 250 µl with culture medium and added to the well. Sufficient BMP-2, ascorbic acid and beta-glycerophosphate was then added to each well to give concentrations of 100 ng/ml, 50 µM and 10mM, respectively. Cells in each of the treatment groups were harvested 96 hours after addition of siRNA duplexes and BMP-2. Total RNA was isolated from the cells using Trizol® and the RNA was quantitated using a spectrophotometer set at 260 nm. 50 ng of total RNA was assayed in duplicate using the TaqMan® assay (Perkin-Elmer) in singleplex format where each target gene in each RNA sample was assayed versus a reference mRNA which was shown previously to be constitutively expressed and not regulated by any of the osteogenic treatments. The Ct values of the target and reference gene were analyzed and the delta Ct values were calculated for each RNA sample. Fold change (expressed as relative expression) was plotted versus cell treatment. For measurement of 76032 transcripts expression was relative to the delta Ct value (Target Ct minus Reference Ct) for control duplex treated cells. For measurement of alkaline phosphatase expression was relative to BMP-2 control cells.

Figure 9A shows expression levels of alkaline phosphatase mRNA, a marker of osteoblast differentiation, in human mesenchymal stromal cells treated with BMP-2 or in combination with siRNA duplex or control duplex as assayed by quantitative RT-PCR. Expression of alkaline phosphatase, and therefore osteoblast differentiation, was significantly increased by treatment of cells with the siRNA duplex. Figure 9B shows expression levels of the target mRNA (76032) in the same human mesenchymal stromal cells, demonstrating significant inhibition of the target gene by the siRNA duplex.

Although the present invention has been described in detail with reference to examples above, it is understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims. All cited patents, patent applications and publications referred to in this application are herein incorporated by reference in their entirety.



We claim:

1. An isolated nucleic acid molecule selected from the group consisting of: (a) an isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1; (b) an isolated nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of  
5 SEQ ID NO: 2; (c) an isolated nucleic acid molecule that encodes a polypeptide fragment of at least about 1,015 amino acids of SEQ ID NO: 2; and (d) an isolated nucleic acid molecule that encodes a polypeptide that exhibits at least about 75% amino acid sequence identity to SEQ ID NO: 2.
- 10 2. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule comprises nucleotides 251-4,336 of SEQ ID NO: 1.
3. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule consists of nucleotides 251-4,336 of SEQ ID NO: 1.
- 15 4. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule comprises nucleotides 251-4333 of SEQ ID NO: 1.
5. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule  
20 consists of nucleotides 251-4333 of SEQ ID NO: 1.
6. The isolated nucleic acid molecule of any one of claims 1-5, wherein said nucleic acid molecule is operably linked to one or more expression control elements.
- 25 7. A vector comprising an isolated nucleic acid molecule of any one of claims 1-5.
8. A host cell transformed to contain the nucleic acid molecule of any one of claims 1-5.
- 30 9. A host cell comprising the vector of claim 8.
10. The host cell of claim 9, wherein said host is selected from the group consisting of prokaryotic host cells and eukaryotic host cells.
- 35 11. A method for producing a polypeptide comprising culturing a host cell transformed

with the nucleic acid molecule of any one of claims 1-5 under conditions in which the polypeptide encoded by said nucleic acid molecule is expressed.

12. The method of claim 11, wherein said host cell is selected from the group consisting  
5 of prokaryotic host cells and eukaryotic host cells.

13. An isolated polypeptide produced by the method of claim 11.

14. An isolated polypeptide selected from the group consisting of: (a) an isolated  
10 polypeptide comprising the amino acid sequence of SEQ ID NO: 2; (b) an isolated polypeptide comprising a fragment of at least 1015 amino acids of SEQ ID NO: 2; (c) an isolated polypeptide comprising conservative amino acid substitutions of SEQ ID NO: 2; and (d) an isolated polypeptide exhibiting at least about 75% amino acid sequence identity with SEQ ID  
15 NO: 2.

15. The isolated polypeptide of claim 15, wherein the polypeptide comprises SEQ ID  
NO: 2.

16. An isolated antibody that binds to a polypeptide of either claim 14 or 15.  
20

17. An antibody of claim 16 wherein said antibody is a monoclonal or a polyclonal  
antibody.

18. A method of screening for an agent that modulates the differentiation of a  
25 population of stem cells into osteoblast cells comprising:

(a) exposing a population of stem cells to the agent, and  
(b) measuring expression or activity of a nucleic acid molecule of claim 1 or a  
polypeptide encoded by the nucleic acid of claim 1 following exposure to the agent, wherein an  
decrease in the level of expression or activity is indicative of an agent capable of stimulating  
30 stem cells to differentiate into osteoblast cells.

19. A method of screening for an agent that increases bone density comprising:

(a) exposing a population of stem cells to the agent; and  
(b) measuring expression or activity of a nucleic acid molecule of claim 1 or a  
35 polypeptide encoded by the nucleic acid of claim 1 following exposure to the agent, wherein a

decrease in the level of expression or activity is indicative of an agent capable increasing bone density.

5           20. A method of diagnosing a condition characterized by abnormal stem cell differentiation comprising detecting in a stem cell sample the level of expression or activity of a nucleic acid molecule of claim 1 or a polypeptide encoded by the nucleic acid of claim 1, wherein abnormal expression or activity is indicative of a condition characterized by abnormal stem cell differentiation.

10           21. A method of diagnosing a condition characterized by abnormal bone density comprising detecting in a stem cell sample the level of expression or activity of a nucleic acid molecule of claim 1 or a polypeptide encoded by the nucleic acid of claim 1, wherein a decrease in expression or activity is indicative of a condition characterized by abnormal bone density.

15           22. The method of claim 20 or 21 wherein the condition is osteoporosis.

          23. A non-human transgenic animal comprising a nucleic acid molecule of claim 1.

20           24. A non-human transgenic animal that is engineered to not express a protein encoded by a nucleic acid molecule of claim 1.

Figure 1A




Figure 1B




Figure 2A




Figure 2B




Figure 3A




Figure 3B




Figure 3C




Figure 4




Figure 5: Human Tissue Panel Expression











Figure 6



**Figure 7: Northern Analysis of Human Tissue Panel**

**Figure 8: Northern Analysis of Human Stem Cell Samples**

**Figure 9**

## SEQUENCE LISTING

<110> Gene Logic, Inc.  
Mertz, Lawrence  
Jaiswal, Neelam  
Houghton, Adam  
Ji, Darren  
Cook, Jonathan S.  
Axelrod, Douglas W.

<120> Gene Associated with Bone Disorders

<130> 44921-5087-WO

<140>

<141>

<150> US 60/309,495

<151> 2001-08-03

<150> US 60/317,975

<151> 2001-09-10

<160> 9

<170> PatentIn version 3.1

<210> 1

<211> 7084

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (251) .. (4336)

<223>

<400> 1

```

cggacgcgtg ggcagcgcgg tgctatcgga cagagcctgg cgagcgcaag cggcgcgggg      60
-agccagcggg gctgagcgcg gccaggggtct gaaccagat ttccagact agctaccact      120
ccgcttgccc acgccccggg agctcgcggc gcctggcggt cagcgaccag acgtccgggg      180
ccgctgcgct cctggccggc gaggcgtgac actgtctcgg ctacagaccc agagggagca      240
cactgccagg atg gga gct gct ggg agg cag gac ttc ctc ttc aag gcc      289
      Met Gly Ala Ala Gly Arg Gln Asp Phe Leu Phe Lys Ala
          1             5             10

atg ctg acc atc agc tgg ctc act ctg acc tgc ttc cct ggg gcc aca      337
Met Leu Thr Ile Ser Trp Leu Thr Leu Thr Cys Phe Pro Gly Ala Thr
      15             20             25

tcc aca gtg gct gct ggg tgc cct gac cag agc cct gag ttg caa ccc      385
Ser Thr Val Ala Ala Gly Cys Pro Asp Gln Ser Pro Glu Leu Gln Pro
      30             35             40             45

tgg aac cct ggc cat gac caa gac cac cat gtg cat atc ggc cag ggc      433
Trp Asn Pro Gly His Asp Gln Asp His His Val His Ile Gly Gln Gly
          50             55             60

```

aag aca ctg ctg ctc acc tct tct gcc acg gtc tat tcc atc cac atc Lys Thr Leu Leu Leu Thr Ser Ser Ala Thr Val Tyr Ser Ile His Ile 65 70 75	481
tca gag gga ggc aag ctg gtc att aaa gac cac gac gag ccg att gtt Ser Glu Gly Gly Lys Leu Val Ile Lys Asp His Asp Glu Pro Ile Val 80 85 90	529
ttg cga acc cgg cac atc ctg att gac aac gga gga gag ctg cat gct Leu Arg Thr Arg His Ile Leu Ile Asp Asn Gly Gly Glu Leu His Ala 95 100 105	577
ggg agt gcc ctc tgc cct ttc cag ggc aat ttc acc atc att ttg tat Gly Ser Ala Leu Cys Pro Phe Gln Gly Asn Phe Thr Ile Ile Leu Tyr 110 115 120 125	625
gga agg gct gat gaa ggt att cag ccg gat cct tac tat ggt ctg aag Gly Arg Ala Asp Glu Gly Ile Gln Pro Asp Pro Tyr Tyr Gly Leu Lys 130 135 140	673
tac att ggg gtt ggt aaa gga ggc gct ctt gag ttg cat gga cag aaa Tyr Ile Gly Val Gly Lys Gly Gly Ala Leu Glu Leu His Gly Gln Lys 145 150 155	721
aag ctc tcc tgg aca ttt ctg aac aag acc ctt cac cca ggt ggc atg Lys Leu Ser Trp Thr Phe Leu Asn Lys Thr Leu His Pro Gly Gly Met 160 165 170	769
gca gaa gga ggc tat ttt ttt gaa agg agc tgg ggc cac cgt gga gtt Ala Glu Gly Gly Tyr Phe Phe Glu Arg Ser Trp Gly His Arg Gly Val 175 180 185	817
att gtt cat gtc atc gac ccc aaa tca ggc aca gtc atc cat tct gac Ile Val His Val Ile Asp Pro Lys Ser Gly Thr Val Ile His Ser Asp 190 195 200 205	865
cgg ttt gac acc tat aga tcc aag aaa gag agt gaa cgt ctg gtc cag Arg Phe Asp Thr Tyr Arg Ser Lys Lys Glu Ser Glu Arg Leu Val Gln 210 215 220	913
tat ttg aac gcg gtg ccc gat ggc agg atc ctt tct gtt gca gtg aat Tyr Leu Asn Ala Val Pro Asp Gly Arg Ile Leu Ser Val Ala Val Asn 225 230 235	961
gat gaa ggt tct cga aat ctg gat gac atg gcc agg aag gcg atg acc Asp Glu Gly Ser Arg Asn Leu Asp Asp Met Ala Arg Lys Ala Met Thr 240 245 250	1009
aaa ttg gga agc aaa cac ttc ctg cac ctt gga ttt aga cac cct tgg Lys Leu Gly Ser Lys His Phe Leu His Leu Gly Phe Arg His Pro Trp 255 260 265	1057
agt ttt cta act gtg aaa gga aat cca tca tct tca gtg gaa gac cat Ser Phe Leu Thr Val Lys Gly Asn Pro Ser Ser Ser Val Glu Asp His 270 275 280 285	1105
att gaa tat cat gga cat cga ggc tct gct gct gcc cgg gta ttc aaa Ile Glu Tyr His Gly His Arg Gly Ser Ala Ala Arg Val Phe Lys 290 295 300	1153

ttg ttc cag aca gag cat ggc gaa tat ttc aat gtt tct ttg tcc agt Leu Phe Gln Thr Glu His Gly Glu Tyr Phe Asn Val Ser Leu Ser Ser 305 310 315	1201
gag tgg gtt caa gac gtg gag tgg acg gag tgg ttc gat cat gat aaa Glu Trp Val Gln Asp Val Glu Trp Thr Glu Trp Phe Asp His Asp Lys 320 325 330	1249
gta tct cag act aaa ggt ggg gag aaa att tca gac ctc tgg aaa gct Val Ser Gln Thr Lys Gly Gly Glu Lys Ile Ser Asp Leu Trp Lys Ala 335 340 345	1297
cac cca gga aaa ata tgc aat cgt ccc att gat ata cag gcc act aca His Pro Gly Lys Ile Cys Asn Arg Pro Ile Asp Ile Gln Ala Thr Thr 350 355 360 365	1345
atg gat gga gtt aac ctc agc acc gag gtt gtc tac aaa aaa ggc cag Met Asp Gly Val Asn Leu Ser Thr Glu Val Val Tyr Lys Lys Gly Gln 370 375 380	1393
gat tat agg ttt gct tgc tac gac cgg ggc aga gcc tgc cgg agc tac Asp Tyr Arg Phe Ala Cys Tyr Asp Arg Gly Arg Ala Cys Arg Ser Tyr 385 390 395	1441
cgt gta cgg ttc ctc tgt ggg aag cct gtg agg ccc aaa ctc aca gtc Arg Val Arg Phe Leu Cys Gly Lys Pro Val Arg Pro Lys Leu Thr Val 400 405 410	1489
acc att gac acc aat gtg aac agc acc att ctg aac ttg gag gat aat Thr Ile Asp Thr Asn Val Asn Ser Thr Ile Leu Asn Leu Glu Asp Asn 415 420 425	1537
gta cag tca tgg aaa cct gga gat acc ctg gtc att gcc agt act gat Val Gln Ser Trp Lys Pro Gly Asp Thr Leu Val Ile Ala Ser Thr Asp 430 435 440 445	1585
tac tcc atg tac cag gca gaa gag ttc cag gtg ctt ccc tgc aga tcc Tyr Ser Met Tyr Gln Ala Glu Glu Phe Gln Val Leu Pro Cys Arg Ser 450 455 460	1633
tgc gcc ccc aac cag gtc aaa gtg gca ggg aaa cca atg tac ctg cac Cys Ala Pro Asn Gln Val Lys Val Ala Gly Lys Pro Met Tyr Leu His 465 470 475	1681
atc ggg gag gag ata gac ggc gtg gac atg cgg gcg gag gtt ggg ctt Ile Gly Glu Glu Ile Asp Gly Val Asp Met Arg Ala Glu Val Gly Leu 480 485 490	1729
ctg agc cgg aac atc ata gtg atg ggg gag atg gag gac aaa tgc tac Leu Ser Arg Asn Ile Ile Val Met Gly Glu Met Glu Asp Lys Cys Tyr 495 500 505	1777
ccc tac aga aac cac atc tgc aat ttc ttt gac ttc gat acc ttt ggg Pro Tyr Arg Asn His Ile Cys Asn Phe Phe Asp Phe Asp Thr Phe Gly 510 515 520 525	1825
ggc cac att aag ttt gct ctg gga ttt aag gca gca cac ttg gag ggc Gly His Ile Lys Phe Ala Leu Gly Phe Lys Ala Ala His Leu Glu Gly 530 535 540	1873
acg gag ctg aag cat atg gga cag cag ctg gtg ggt cag tac ccg att	1921

Thr Glu Leu Lys His Met Gly Gln Gln Leu Val Gly Gln Tyr Pro Ile	
545 550 555	
cac ttc cac ctg gcc ggt gat gta gac gaa agg gga ggt tat gac cca	1969
His Phe His Leu Ala Gly Asp Val Asp Glu Arg Gly Gly Tyr Asp Pro	
560 565 570	
ccc aca tac atc agg gac ctc tcc atc cat cat aca ttc tct cgc tgc	2017
Pro Thr Tyr Ile Arg Asp Leu Ser Ile His His Thr Phe Ser Arg Cys	
575 580 585	
gtc aca gtc cat ggc tcc aat ggc ttg ttg atc aag gac gtt gtg ggc	2065
Val Thr Val His Gly Ser Asn Gly Leu Leu Ile Lys Asp Val Val Gly	
590 595 600 605	
tat aac tct ttg ggc cac tgc ttc ttc acg gaa gat ggg ccg gag gaa	2113
Tyr Asn Ser Leu Gly His Cys Phe Phe Thr Glu Asp Gly Pro Glu Glu	
610 615 620	
cgc aac act ttt gac cac tgc ctt ggc ctc ctt gtc aag tct gga acc	2161
Arg Asn Thr Phe Asp His Cys Leu Gly Leu Leu Val Lys Ser Gly Thr	
625 630 635	
ctc ctc ccc tcg gac cgt gac agc aag atg tgc aag atg atc aca gag	2209
Leu Leu Pro Ser Asp Arg Asp Ser Lys Met Cys Lys Met Ile Thr Glu	
640 645 650	
gac tcc tac cca ggg tac atc ccc aag ccc agg caa gac tgc aat gct	2257
Asp Ser Tyr Pro Gly Tyr Ile Pro Lys Pro Arg Gln Asp Cys Asn Ala	
655 660 665	
gtg tcc acc ttc tgg atg gcc aat ccc aac aac aac ctc atc aac tgt	2305
Val Ser Thr Phe Trp Met Ala Asn Pro Asn Asn Asn Leu Ile Asn Cys	
670 675 680 685	
gcc gct tca gga tct gag gaa act gga ttt tgg ttt att ttt cac cac	2353
Ala Ala Ser Gly Ser Glu Glu Thr Gly Phe Trp Phe Ile Phe His His	
690 695 700	
gta cca acg ggc ccc tcc gtg gga atg tac tcc cca ggt tat tca gag	2401
Val Pro Thr Gly Pro Ser Val Gly Met Tyr Ser Pro Gly Tyr Ser Glu	
705 710 715	
cac att cca ctg gga aaa ttc tat aac aac cga gca cat tcc aac tac	2449
His Ile Pro Leu Gly Lys Phe Tyr Asn Asn Arg Ala His Ser Asn Tyr	
720 725 730	
cgg gct ggc atg atc ata gac aac gga gtc aaa acc acc gag gcc tct	2497
Arg Ala Gly Met Ile Ile Asp Asn Gly Val Lys Thr Thr Glu Ala Ser	
735 740 745	
gcc aag gac aag cgg ccg ttc ctc tca atc atc tct gcc aga tac agc	2545
Ala Lys Asp Lys Arg Pro Phe Leu Ser Ile Ile Ser Ala Arg Tyr Ser	
750 755 760 765	
cct cac cag gac gcc gac ccg ctg aag ccc cgg gag ccg gcc atc atc	2593
Pro His Gln Asp Ala Asp Pro Leu Lys Pro Arg Glu Pro Ala Ile Ile	
770 775 780	
aga cac ttc att gcc tac aag aac cag gac cac ggg gcc tgg ctg cgc	2641
Arg His Phe Ile Ala Tyr Lys Asn Gln Asp His Gly Ala Trp Leu Arg	



785	790	795	
ggc ggg gat gtg tgg ctg gac agc tgc cgg ttt gct gac aat ggc att Gly Gly Asp Val Trp Leu Asp Ser Cys Arg Phe Ala Asp Asn Gly Ile 800 805 810			2689
ggc ctg acc ctg gcc agt ggt gga acc ttc ccg tat gac gac ggc tcc Gly Leu Thr Leu Ala Ser Gly Gly Thr Phe Pro Tyr Asp Asp Gly Ser 815 820 825			2737
aag caa gag ata aag aac agc ttg ttt gtt ggc gag agt ggc aac gtg Lys Gln Glu Ile Lys Asn Ser Leu Phe Val Gly Glu Ser Gly Asn Val 830 835 840 845			2785
ggg acg gaa atg atg gac aat agg atc tgg ggc cct ggc ggc ttg gac Gly Thr Glu Met Met Asp Asn Arg Ile Trp Gly Pro Gly Gly Leu Asp 850 855 860			2833
cat agc gga agg acc ctc cct ata ggc cag aat ttt cca att aga gga His Ser Gly Arg Thr Leu Pro Ile Gly Gln Asn Phe Pro Ile Arg Gly 865 870 875			2881
att cag tta tat gat ggc ccc atc aac atc caa aac tgc act ttc cga Ile Gln Leu Tyr Asp Gly Pro Ile Asn Ile Gln Asn Cys Thr Phe Arg 880 885 890			2929
aag ttt gtg gcc ctg gag ggc cgg cac acc agc gcc ctg gcc ttc cgc Lys Phe Val Ala Leu Glu Gly Arg His Thr Ser Ala Leu Ala Phe Arg 895 900 905			2977
ctg aat aat gcc tgg cag agc tgc ccc cat aac aac gtg acc ggc att Leu Asn Asn Ala Trp Gln Ser Cys Pro His Asn Asn Val Thr Gly Ile 910 915 920 925			3025
gcc ttt gag gac gtt ccg att act tcc aga gtg ttc ttc gga gag cct Ala Phe Glu Asp Val Pro Ile Thr Ser Arg Val Phe Phe Gly Glu Pro 930 935 940			3073
ggg ccc tgg ttc aac cag ctg gac atg gat ggg gat aag aca tct gtg Gly Pro Trp Phe Asn Gln Leu Asp Met Asp Gly Asp Lys Thr Ser Val 945 950 955			3121
ttc cat gac gtc gac ggc tcc gtg tcc gag tac cct ggc tcc tac ctc Phe His Asp Val Asp Gly Ser Val Ser Glu Tyr Pro Gly Ser Tyr Leu 960 965 970			3169
acg aag aat gac aac tgg ctg gtc cgg cac cca gac tgc atc aat gtt Thr Lys Asn Asp Asn Trp Leu Val Arg His Pro Asp Cys Ile Asn Val 975 980 985			3217
ccc gac tgg aga ggg gcc att tgc agt ggg tgc tat gca cag atg tac Pro Asp Trp Arg Gly Ala Ile Cys Ser Gly Cys Tyr Ala Gln Met Tyr 990 995 1000 1005			3265
att caa gcc tac aag acc agt aac ctg cga atg aag atc atc aag Ile Gln Ala Tyr Lys Thr Ser Asn Leu Arg Met Lys Ile Ile Lys 1010 1015 1020			3310
aat gac ttc ccc agc cac cct ctt tac ctg gag ggg gcg ctc acc Asn Asp Phe Pro Ser His Pro Leu Tyr Leu Glu Gly Ala Leu Thr 1025 1030 1035			3355

agg agc acc cat tac	cag caa tac caa ccg	gtt gtc acc ctg cag	3400
Arg Ser Thr His Tyr	Gln Gln Tyr Gln Pro	Val Val Thr Leu Gln	
1040	1045	1050	
aag ggc tac acc atc	cac tgg gac cag acg	gcc ccc gcc gaa ctc	3445
Lys Gly Tyr Thr Ile	His Trp Asp Gln Thr	Ala Pro Ala Glu Leu	
1055	1060	1065	
gcc atc tgg ctc atc	aac ttc aac aag ggc	gac tgg atc cga gtg	3490
Ala Ile Trp Leu Ile	Asn Phe Asn Lys Gly	Asp Trp Ile Arg Val	
1070	1075	1080	
ggg ctc tgc tac ccg	cga ggc acc aca ttc	tcc atc ctc tcg gat	3535
Gly Leu Cys Tyr Pro	Arg Gly Thr Thr Phe	Ser Ile Leu Ser Asp	
1085	1090	1095	
gtt cac aat cgc ctg	ctg aag caa acg tcc	aag acg ggc gtc ttc	3580
Val His Asn Arg Leu	Leu Lys Gln Thr Ser	Lys Thr Gly Val Phe	
1100	1105	1110	
gtg agg acc ttg cag	atg gac aaa gtg gag	cag agc tac cct ggc	3625
Val Arg Thr Leu Gln	Met Asp Lys Val Glu	Gln Ser Tyr Pro Gly	
1115	1120	1125	
agg agc cac tac tac	tgg gac gag gac tca	ggg ctg ttg ttc ctg	3670
Arg Ser His Tyr Tyr	Trp Asp Glu Asp Ser	Gly Leu Leu Phe Leu	
1130	1135	1140	
aag ctg aaa gct cag	aac gag aga gag aag	ttt gct ttc tgc tcc	3715
Lys Leu Lys Ala Gln	Asn Glu Arg Glu Lys	Phe Ala Phe Cys Ser	
1145	1150	1155	
atg aaa ggc tgt gag	agg ata aag att aaa	gct ctg att cca aag	3760
Met Lys Gly Cys Glu	Arg Ile Lys Ile Lys	Ala Leu Ile Pro Lys	
1160	1165	1170	
aac gca ggc gtc agt	gac tgc aca gcc aca	gct tac ccc aag ttc	3805
Asn Ala Gly Val Ser	Asp Cys Thr Ala Thr	Ala Tyr Pro Lys Phe	
1175	1180	1185	
acc gag agg gct gtc	gta gac gtg ccg atg	ccc aag aag ctc ttt	3850
Thr Glu Arg Ala Val	Val Asp Val Pro Met	Pro Lys Lys Leu Phe	
1190	1195	1200	
ggg tct cag ctg aaa	aca aag gac cat ttc	ttg gag gtg aag atg	3895
Gly Ser Gln Leu Lys	Thr Lys Asp His Phe	Leu Glu Val Lys Met	
1205	1210	1215	
gag agt tcc aag cag	cac ttc ttc cac ctc	tgg aac gac ttc gct	3940
Glu Ser Ser Lys Gln	His Phe Phe His Leu	Trp Asn Asp Phe Ala	
1220	1225	1230	
tac att gaa gtg gat	ggg aag aag tac ccc	agt tcg gag gat ggc	3985
Tyr Ile Glu Val Asp	Gly Lys Lys Tyr Pro	Ser Ser Glu Asp Gly	
1235	1240	1245	
atc cag gtg gtg gtg	att gac ggg aac caa	ggg cgc gtg gtg agc	4030
Ile Gln Val Val Val	Ile Asp Gly Asn Gln	Gly Arg Val Val Ser	
1250	1255	1260	

cac acg agc ttc agg	aac tcc att ctg caa	ggc ata cca tgg cag	4075
His Thr Ser Phe Arg	Asn Ser Ile Leu Gln	Gly Ile Pro Trp Gln	
1265	1270	1275	
ctt ttc aac tat gtg	gcg acc atc cct gac	aat tcc ata gtg ctt	4120
Leu Phe Asn Tyr Val	Ala Thr Ile Pro Asp	Asn Ser Ile Val Leu	
1280	1285	1290	
atg gca tca aag gga	aga tac gtc tcc aga	ggc cca tgg acc aga	4165
Met Ala Ser Lys Gly	Arg Tyr Val Ser Arg	Gly Pro Trp Thr Arg	
1295	1300	1305	
gtg ctg gaa aag ctt	ggg gca gac agg ggt	ctc aag ttg aaa gag	4210
Val Leu Glu Lys Leu	Gly Ala Asp Arg Gly	Leu Lys Leu Lys Glu	
1310	1315	1320	
caa atg gca ttc gtt	ggc ttc aaa ggc agc	ttc cgg ccc atc tgg	4255
Gln Met Ala Phe Val	Gly Phe Lys Gly Ser	Phe Arg Pro Ile Trp	
1325	1330	1335	
gtg aca ctg gac act	gag gat cac aaa gcc	aaa atc ttc caa gtt	4300
Val Thr Leu Asp Thr	Glu Asp His Lys Ala	Lys Ile Phe Gln Val	
1340	1345	1350	
gtg ccc atc cct gtg	gtg aag aag aag aag	ttg tga ggacagctgc	4346
Val Pro Ile Pro Val	Val Lys Lys Lys Lys	Leu	
1355	1360		
cgccccggtgc cacctcgtgg	tagactatga cggtgactct	tggcagcaga ccagtggggg	4406
atggctgggt cccccagccc	ctgccagcag ctgcctggga	aggccgtgtt tcagccctga	4466
tgggccaagg gaaggctatc	agagaccctg gtgctgccac	ctgcccctac tcaagtgtct	4526
acctggagcc cctggggcgg	tgctggccaa tgctggaaac	attcactttc ctgcagcctc	4586
ttgggtgctt ctctcctatc	tgtgcctctt cagtgggggt	ttggggacca tatcaggaga	4646
cctgggttgt gctgacagca	aagatccact ttggcaggag	ccctgaccca gctaggaggt	4706
agtctggagg gctggtcatt	cacagatccc catggtcttc	agcagacaag tgagggtggt	4766
aaatgtagga gaaagagcct	tggccttaag gaaatcttta	ctcctgtaag caagagccaa	4826
cctcacagga ttaggagctg	gggtagaact ggctatcctt	ggggaagagg caagccctgc	4886
ctctggccgt gtccaccttt	caggagactt tgagtggcag	gtttggactt ggactagatg	4946
actctcaaag gcccttttag	ttctgagatt ccagaaatct	gctgcatttc acatggtacc	5006
tggaacccaa cagttcatgg	atatccactg atatccatga	tgctgggtgc cccagcgcac	5066
acgggatgga gaggtgagaa	ctaatgccta gcttgagggg	tctgcagtcc agtagggcag	5126
gcagtcaggt ccatgtgcac	tgcaatgcca ggtggagaaa	tcacagagag gtaaaatgga	5186
ggccagtgcc atttcagagg	ggaggctcag gaaggcttct	tgcttacagg aatgaaggct	5246
gggggcattt tgctgggggg	agatgaggca gcctctggaa	tggtcaggg attcagccct	5306
ccctgccgct gcctgctgaa	gctgggtgact acggggctgc	cctttgctca cgtctctctg	5366

gccactcat gatggagaag tgtggtcaga ggggagcaat gggctttgct gcttatgagc 5426  
 acagaggaat tcagtcccca ggcagccctg cctctgactc caagaggggtg aagtccacag 5486  
 aagtgagctc ctgccttagg gcctcatttg ctcttcatcc agggaaactga gcacaggggg 5546  
 cctccaggag accctagatg tgctcgtact ccctcggcct gggatttcag agctggaaat 5606  
 atagaaaata tctagcccaa agccttcatt ttaacagatg gggaaagtga gcccccaaga 5666  
 tgggaaagaa ccacacagct aaggaggggc ctggggagcc ccaccctagc ccttgctgcc 5726  
 acaccacatt gctcaacaa ccggcccccag agtgcccagg cactcctgag gtagcttctg 5786  
 gaaatgggga caagtccct cgaaggaaag gaaatgacta gagtagaatg acagctagca 5846  
 gatctcttcc ctctgctcc cagcgcacac aaaccgccc tccccttggg gttggcggtc 5906  
 cctgtggcct tcactttgtt cactacctgt cagcccagcc tgggtgcaca gtagctgcaa 5966  
 ctcccattg gtgctacctg gctctcctgt ctctgcagct ctacaggtga ggcccagcag 6026  
 agggagtagg gctcgccatg tttctggtga gccaatgtg ctgatcttgg gtgtctgaac 6086  
 agctattggg tccaccccag tccctttcag ctgctgctta atgccctgct ctctccctgg 6146  
 cccaccttat agagagccca aagagctcct gtaagaggga gaactctatc tgtggtttat 6206  
 aatcttgac gaggcaccag agtctccctg ggtcttgtga tgaactacat ttatcccctt 6266  
 tctgccccca accacaaact ctttccttca aagagggcct gcctggctcc ctccacccaa 6326  
 ctgcacccat gagactcggg ccaagagtcc attccccagg tgggagccaa ctgtcagggg 6386  
 ggtctttccc accaaacatc tttcagctgc tgggaggtga ccatagggct ctgcttttaa 6446  
 agatatggct gcttcaaagg ccagagtcac aggaaggact tcttcaggg agattagtgg 6506  
 tgatggagag gagagttaaa atgacctcat gtccttcttg tccacggtt tgttgagttt 6566  
 tcactcttct aatgcaaggg tctcacactg tgaaccaatt aggatgtgat cactttcagg 6626  
 tggccaggaa tgttgaatgt ctttggctca gttcatttaa aaaagatata tatttgaaag 6686  
 ttctcagagt tgtacatatg tttcacagta caggatctgt acataaaagt ttctttccta 6746  
 aaccattcac caagagccaa tatctaggca tttcttggg agcacaaatt ttcttattgc 6806  
 ttagaaaatt gtctccttg ttatttctgt ttgtaagact taagtgagtt aggtctttaa 6866  
 ggaaagcaac gtcctctga aatgcttgct tttttctgt tgccgaaata gctggctcct 6926  
 tttcgggagt tagatgtata gagtgttgt atgtaaacad ttctttagg catcaccatg 6986  
 aacaaagata tattttctat ttatttatta tatgtgcact tcaagaagtc actgtcagag 7046  
 aaataaagaa ttgtcttaaa tgtaaaaaaa aaaaaaa 7084

<211> 1361  
 <212> PRT  
 <213> Homo sapiens

<400> 2

Met Gly Ala Ala Gly Arg Gln Asp Phe Leu Phe Lys Ala Met Leu Thr  
 1 5 10 15

Ile Ser Trp Leu Thr Leu Thr Cys Phe Pro Gly Ala Thr Ser Thr Val  
 20 25 30

Ala Ala Gly Cys Pro Asp Gln Ser Pro Glu Leu Gln Pro Trp Asn Pro  
 35 40 45

Gly His Asp Gln Asp His His Val His Ile Gly Gln Gly Lys Thr Leu  
 50 55 60

Leu Leu Thr Ser Ser Ala Thr Val Tyr Ser Ile His Ile Ser Glu Gly  
 65 70 75 80

Gly Lys Leu Val Ile Lys Asp His Asp Glu Pro Ile Val Leu Arg Thr  
 85 90 95

Arg His Ile Leu Ile Asp Asn Gly Gly Glu Leu His Ala Gly Ser Ala  
 100 105 110

Leu Cys Pro Phe Gln Gly Asn Phe Thr Ile Ile Leu Tyr Gly Arg Ala  
 115 120 125

Asp Glu Gly Ile Gln Pro Asp Pro Tyr Tyr Gly Leu Lys Tyr Ile Gly  
 130 135 140

Val Gly Lys Gly Gly Ala Leu Glu Leu His Gly Gln Lys Lys Leu Ser  
 145 150 155 160

Trp Thr Phe Leu Asn Lys Thr Leu His Pro Gly Gly Met Ala Glu Gly  
 165 170 175

Gly Tyr Phe Phe Glu Arg Ser Trp Gly His Arg Gly Val Ile Val His  
 180 185 190

Val Ile Asp Pro Lys Ser Gly Thr Val Ile His Ser Asp Arg Phe Asp  
 195 200 205

Thr Tyr Arg Ser Lys Lys Glu Ser Glu Arg Leu Val Gln Tyr Leu Asn  
 210 215 220

Ala Val Pro Asp Gly Arg Ile Leu Ser Val Ala Val Asn Asp Glu Gly  
 225 230 235 240

Ser Arg Asn Leu Asp Asp Met Ala Arg Lys Ala Met Thr Lys Leu Gly  
 245 250 255

Ser Lys His Phe Leu His Leu Gly Phe Arg His Pro Trp Ser Phe Leu  
 260 265 270

Thr Val Lys Gly Asn Pro Ser Ser Ser Val Glu Asp His Ile Glu Tyr  
 275 280 285

His Gly His Arg Gly Ser Ala Ala Ala Arg Val Phe Lys Leu Phe Gln  
 290 295 300

Thr Glu His Gly Glu Tyr Phe Asn Val Ser Leu Ser Ser Glu Trp Val  
 305 310 315 320

Gln Asp Val Glu Trp Thr Glu Trp Phe Asp His Asp Lys Val Ser Gln  
 325 330 335

Thr Lys Gly Gly Glu Lys Ile Ser Asp Leu Trp Lys Ala His Pro Gly  
 340 345 350

Lys Ile Cys Asn Arg Pro Ile Asp Ile Gln Ala Thr Thr Met Asp Gly  
 355 360 365

Val Asn Leu Ser Thr Glu Val Val Tyr Lys Lys Gly Gln Asp Tyr Arg  
 370 375 380

Phe Ala Cys Tyr Asp Arg Gly Arg Ala Cys Arg Ser Tyr Arg Val Arg  
 385 390 395 400

Phe Leu Cys Gly Lys Pro Val Arg Pro Lys Leu Thr Val Thr Ile Asp  
 405 410 415

Thr Asn Val Asn Ser Thr Ile Leu Asn Leu Glu Asp Asn Val Gln Ser  
 420 425 430

Trp Lys Pro Gly Asp Thr Leu Val Ile Ala Ser Thr Asp Tyr Ser Met  
 435 440 445

Tyr Gln Ala Glu Glu Phe Gln Val Leu Pro Cys Arg Ser Cys Ala Pro  
 450 455 460

Asn Gln Val Lys Val Ala Gly Lys Pro Met Tyr Leu His Ile Gly Glu  
 465 470 475 480

Glu Ile Asp Gly Val Asp Met Arg Ala Glu Val Gly Leu Leu Ser Arg  
 485 490 495

Asn Ile Ile Val Met Gly Glu Met Glu Asp Lys Cys Tyr Pro Tyr Arg  
 500 505 510

Asn His Ile Cys Asn Phe Phe Asp Phe Asp Thr Phe Gly Gly His Ile  
 515 520 525

Lys Phe Ala Leu Gly Phe Lys Ala Ala His Leu Glu Gly Thr Glu Leu  
 530 535 540

Lys His Met Gly Gln Gln Leu Val Gly Gln Tyr Pro Ile His Phe His  
 545 550 555 560

Leu Ala Gly Asp Val Asp Glu Arg Gly Gly Tyr Asp Pro Pro Thr Tyr  
 565 570 575

Ile Arg Asp Leu Ser Ile His His Thr Phe Ser Arg Cys Val Thr Val  
 580 585 590

His Gly Ser Asn Gly Leu Leu Ile Lys Asp Val Val Gly Tyr Asn Ser  
 595 600 605

Leu Gly His Cys Phe Phe Thr Glu Asp Gly Pro Glu Glu Arg Asn Thr  
 610 615 620

Phe Asp His Cys Leu Gly Leu Leu Val Lys Ser Gly Thr Leu Leu Pro  
 625 630 635 640

Ser Asp Arg Asp Ser Lys Met Cys Lys Met Ile Thr Glu Asp Ser Tyr  
 645 650 655

Pro Gly Tyr Ile Pro Lys Pro Arg Gln Asp Cys Asn Ala Val Ser Thr  
 660 665 670

Phe Trp Met Ala Asn Pro Asn Asn Asn Leu Ile Asn Cys Ala Ala Ser  
 675 680 685

Gly Ser Glu Glu Thr Gly Phe Trp Phe Ile Phe His His Val Pro Thr  
 690 695 700

Gly Pro Ser Val Gly Met Tyr Ser Pro Gly Tyr Ser Glu His Ile Pro

705 710 715 720

Leu Gly Lys Phe Tyr Asn Asn Arg Ala His Ser Asn Tyr Arg Ala Gly  
725 730 735

Met Ile Ile Asp Asn Gly Val Lys Thr Thr Glu Ala Ser Ala Lys Asp  
740 745 750

Lys Arg Pro Phe Leu Ser Ile Ile Ser Ala Arg Tyr Ser Pro His Gln  
755 760 765

Asp Ala Asp Pro Leu Lys Pro Arg Glu Pro Ala Ile Ile Arg His Phe  
770 775 780

Ile Ala Tyr Lys Asn Gln Asp His Gly Ala Trp Leu Arg Gly Gly Asp  
785 790 795 800

Val Trp Leu Asp Ser Cys Arg Phe Ala Asp Asn Gly Ile Gly Leu Thr  
805 810 815

Leu Ala Ser Gly Gly Thr Phe Pro Tyr Asp Asp Gly Ser Lys Gln Glu  
820 825 830

Ile Lys Asn Ser Leu Phe Val Gly Glu Ser Gly Asn Val Gly Thr Glu  
835 840 845

Met Met Asp Asn Arg Ile Trp Gly Pro Gly Gly Leu Asp His Ser Gly  
850 855 860

Arg Thr Leu Pro Ile Gly Gln Asn Phe Pro Ile Arg Gly Ile Gln Leu  
865 870 875 880

Tyr Asp Gly Pro Ile Asn Ile Gln Asn Cys Thr Phe Arg Lys Phe Val  
885 890 895

Ala Leu Glu Gly Arg His Thr Ser Ala Leu Ala Phe Arg Leu Asn Asn  
900 905 910

Ala Trp Gln Ser Cys Pro His Asn Asn Val Thr Gly Ile Ala Phe Glu  
915 920 925

Asp Val Pro Ile Thr Ser Arg Val Phe Phe Gly Glu Pro Gly Pro Trp  
930 935 940

Phe Asn Gln Leu Asp Met Asp Gly Asp Lys Thr Ser Val Phe His Asp  
945 950 955 960



13

Ala Val Val Asp Val Pro Met Pro Lys Lys Leu Phe Gly Ser Gln  
 1190 1195 1200

Leu Lys Thr Lys Asp His Phe Leu Glu Val Lys Met Glu Ser Ser  
 1205 1210 1215

Lys Gln His Phe Phe His Leu Trp Asn Asp Phe Ala Tyr Ile Glu  
 1220 1225 1230

Val Asp Gly Lys Lys Tyr Pro Ser Ser Glu Asp Gly Ile Gln Val  
 1235 1240 1245

Val Val Ile Asp Gly Asn Gln Gly Arg Val Val Ser His Thr Ser  
 1250 1255 1260

Phe Arg Asn Ser Ile Leu Gln Gly Ile Pro Trp Gln Leu Phe Asn  
 1265 1270 1275

Tyr Val Ala Thr Ile Pro Asp Asn Ser Ile Val Leu Met Ala Ser  
 1280 1285 1290

Lys Gly Arg Tyr Val Ser Arg Gly Pro Trp Thr Arg Val Leu Glu  
 1295 1300 1305

Lys Leu Gly Ala Asp Arg Gly Leu Lys Leu Lys Glu Gln Met Ala  
 1310 1315 1320

Phe Val Gly Phe Lys Gly Ser Phe Arg Pro Ile Trp Val Thr Leu  
 1325 1330 1335

Asp Thr Glu Asp His Lys Ala Lys Ile Phe Gln Val Val Pro Ile  
 1340 1345 1350

Pro Val Val Lys Lys Lys Lys Leu  
 1355 1360

<210> 3  
 <211> 55  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> PCR Primer

<220>  
 <221> misc\_feature  
 <222> (55)..(55)  
 <223> v can be a or g or c

<400> 3  
acgtaatacg actcactata gggcgaattg ggtcgacttt tttttttttt ttttv 55

<210> 4  
<211> 40  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RP5 PCR Primer

<400> 4  
ctctcaagga tcttaccgct tttttttttt ttttttttat 40

<210> 5  
<211> 40  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RP6 PCR Primer

<400> 5  
taataccgcg ccacatagca tttttttttt ttttttttcg 40

<210> 6  
<211> 40  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> RP92 PCR Primer

<400> 6  
cagggtagac gacgctacgc tttttttttt ttttttttga 40

<210> 7  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Adapter oligonucleotide sequence A1

<400> 7  
tagcgtccgg cgcagcgacg gccag 25

<210> 8  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Adapter oligonucleotide sequence A2

<400> 8  
gatacctggcc gtcggctgtc tgcggcgc

29

<210> 9  
<211> 40  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR Primer

<220>  
<221> misc\_feature  
<222> (39)..(39)  
<223> v can be a or g or c

<220>  
<221> misc\_feature  
<222> (40)..(40)  
<223> n can be a or c or g or t

<400> 9  
tgaagccgag acgtcggtcg tttttttttt ttttttttvn

40